<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">75594</article-id><article-id pub-id-type="doi">10.7554/eLife.75594</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>C/EBPδ-induced epigenetic changes control the dynamic gene transcription of <italic>S100a8</italic> and <italic>S100a9</italic></article-title></title-group><contrib-group><contrib contrib-type="author" id="author-262967"><name><surname>Jauch-Speer</surname><given-names>Saskia-Larissa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6739-3051</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262963"><name><surname>Herrera-Rivero</surname><given-names>Marisol</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7064-9487</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-277456"><name><surname>Ludwig</surname><given-names>Nadine</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-277457"><name><surname>Véras De Carvalho</surname><given-names>Bruna Caroline</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262962"><name><surname>Martens</surname><given-names>Leonie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262961"><name><surname>Wolf</surname><given-names>Jonas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262964"><name><surname>Imam Chasan</surname><given-names>Achmet</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5137-6890</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-122979"><name><surname>Witten</surname><given-names>Anika</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-262965"><name><surname>Markus</surname><given-names>Birgit</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-262966"><name><surname>Schieffer</surname><given-names>Bernhard</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72270"><name><surname>Vogl</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216698"><name><surname>Rossaint</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-96604"><name><surname>Stoll</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-72271"><name><surname>Roth</surname><given-names>Johannes</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7035-8348</contrib-id><email>rothj@uni-muenster.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260886"><name><surname>Fehler</surname><given-names>Olesja</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6386-7080</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00pd74e08</institution-id><institution>Institute of Immunology, University of Münster</institution></institution-wrap><addr-line><named-content content-type="city">Münster</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00pd74e08</institution-id><institution>Department of Genetic Epidemiology, Institute of Human Genetics, University of Münster</institution></institution-wrap><addr-line><named-content content-type="city">Münster</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01856cw59</institution-id><institution>Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster</institution></institution-wrap><addr-line><named-content content-type="city">Münster</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00pd74e08</institution-id><institution>Core Facility Genomics, Medical Faculty Münster, University of Münster</institution></institution-wrap><addr-line><named-content content-type="city">Münster</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032nzv584</institution-id><institution>Clinic for Cardiology, Angiology and Internal Intensive Medicine, University Hospital Marburg</institution></institution-wrap><addr-line><named-content content-type="city">Marburg</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jz4aj89</institution-id><institution>CARIM Cardiovascular Research School, Department of Biochemistry, Genetic Epidemiology and Statistical Genetics, Maastricht University</institution></institution-wrap><addr-line><named-content content-type="city">Maastricht</named-content></addr-line><country>Netherlands</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Rehman</surname><given-names>Jalees</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02mpq6x41</institution-id><institution>University of Illinois at Chicago</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rothlin</surname><given-names>Carla V</given-names></name><role>Senior Editor</role><aff><institution>Yale School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>11</day><month>05</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e75594</elocation-id><history><date date-type="received" iso-8601-date="2021-11-16"><day>16</day><month>11</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-05-06"><day>06</day><month>05</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-12-09"><day>09</day><month>12</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.12.05.471309"/></event></pub-history><permissions><copyright-statement>© 2022, Jauch-Speer et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Jauch-Speer et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-75594-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-75594-figures-v2.pdf"/><abstract><p>The proinflammatory alarmins S100A8 and S100A9 are among the most abundant proteins in neutrophils and monocytes but are completely silenced after differentiation to macrophages. The molecular mechanisms of the extraordinarily dynamic transcriptional regulation of <italic>S100a8</italic> and <italic>S100a9</italic> genes, however, are only barely understood. Using an unbiased genome-wide CRISPR/Cas9 knockout (KO)-based screening approach in immortalized murine monocytes, we identified the transcription factor C/EBPδ as a central regulator of <italic>S100a8</italic> and <italic>S100a9</italic> expression. We showed that S100A8/A9 expression and thereby neutrophil recruitment and cytokine release were decreased in C/EBPδ KO mice in a mouse model of acute lung inflammation. <italic>S100a8</italic> and <italic>S100a9</italic> expression was further controlled by the C/EBPδ antagonists ATF3 and FBXW7. We confirmed the clinical relevance of this regulatory network in subpopulations of human monocytes in a clinical cohort of cardiovascular patients. Moreover, we identified specific C/EBPδ-binding sites within <italic>S100a8</italic> and <italic>S100a9</italic> promoter regions, and demonstrated that C/EBPδ-dependent JMJD3-mediated demethylation of H3K27me<sub>3</sub> is indispensable for their expression. Overall, our work uncovered C/EBPδ as a novel regulator of <italic>S100a8</italic> and <italic>S100a9</italic> expression. Therefore, C/EBPδ represents a promising target for modulation of inflammatory conditions that are characterized by <italic>S100a8</italic> and <italic>S100a9</italic> overexpression.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>C/EBPδ</kwd><kwd>calprotectin</kwd><kwd>CRISPR/Cas9 screen</kwd><kwd>monocytes</kwd><kwd>S100A8/A9</kwd><kwd>human</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>CRC 1009 B9</award-id><principal-award-recipient><name><surname>Roth</surname><given-names>Johannes</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>CRC 1009 Z2</award-id><principal-award-recipient><name><surname>Roth</surname><given-names>Johannes</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>CRC 1009 B8</award-id><principal-award-recipient><name><surname>Vogl</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>CRU 342 P3</award-id><principal-award-recipient><name><surname>Roth</surname><given-names>Johannes</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>RO 1190/14-1</award-id><principal-award-recipient><name><surname>Roth</surname><given-names>Johannes</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>CRU 342 P5</award-id><principal-award-recipient><name><surname>Vogl</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>Interdisciplinary Center of Clinical Research at the University of Münster</institution></institution-wrap></funding-source><award-id>Ro2/023/19</award-id><principal-award-recipient><name><surname>Roth</surname><given-names>Johannes</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Interdisciplinary Center of Clinical Research at the University of Münster</institution></institution-wrap></funding-source><award-id>Vo2/011/19</award-id><principal-award-recipient><name><surname>Vogl</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>EU EFRE Bio NRW programme</institution></institution-wrap></funding-source><award-id>005-1007-0006</award-id><principal-award-recipient><name><surname>Stoll</surname><given-names>Monika</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A genome-wide CRISPR/Cas9 knockout screening approach identified C/EBPδ as transcriptional regulator of the alarmins S100A8 and S100A9 during differentiation of monocytes and inflammatory processes in vivo.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>As the first line of immune defence, both monocytes and neutrophils are important for the modulation of the innate immune response. To amplify the immune response at sites of inflammation, the activation of further immune cells is required, mediated by the release of signaling molecules such as chemokines and DAMPs (damage-associated molecular patterns). The two members of the S100 family, S100A8 and S100A9, also termed myeloid-related proteins 8 and 14 (MRP8 and MRP14), respectively, belong to the group of DAMPs or so-called alarmins. Their primary expression is referred to myeloid lineage-derived cells, particularly neutrophils and monocytes, where S100A8 and S100A9 are predominantly present as a heterodimeric complex, also called calprotectin (<xref ref-type="bibr" rid="bib2">Austermann et al., 2018</xref>).</p><p>Intracellularly, S100A8/A9 complexes represent up to 40% of the soluble protein content in neutrophils and about 5% in monocytes (<xref ref-type="bibr" rid="bib31">Hessian et al., 1993</xref>). However, in mature macrophages, protein and mRNA expression of these factors is completely downregulated. This data indicates that expression of <italic>S100A8</italic> and <italic>S100A9</italic> is controlled by the most dynamic promoters in myeloid cells. The S100A8/A9 complex interacts with the cytoskeleton in a calcium-dependent manner. Calcium-induced (S100A8/A9)<sub>2</sub> tetramer promotes tubulin polymerization and microtubule bundling, thereby affecting transendothelial migration of phagocytes (<xref ref-type="bibr" rid="bib50">Leukert et al., 2006</xref>). During inflammation or tissue damage, S100A8/A9 is actively secreted by neutrophils and monocytes, and represents the most abundant DAMP/alarmin activating inflammatory processes in infection, cancer, autoimmunity, and cardiovascular diseases. The S100A8/A9 complex is recognized by Toll-like receptor 4 (TLR4), which leads to the production of proinflammatory cytokines and chemokines (<xref ref-type="bibr" rid="bib20">Fassl et al., 2015</xref>). Accordingly, S100A9 knockout (KO) mice exhibit decreased pathogenic outcomes in several mouse models of disease, such as sepsis (<xref ref-type="bibr" rid="bib75">Vogl et al., 2007</xref>), autoimmune disease (<xref ref-type="bibr" rid="bib58">Loser et al., 2010</xref>) or arthritis (<xref ref-type="bibr" rid="bib73">van Lent et al., 2008</xref>). In addition, S100A8 and S100A9 are highly abundant during infectious diseases and exhibit anti-microbial activities. The S100A8/A9 complex plays a crucial role in host defence against bacterial and fungal pathogens by sequestering manganese and zinc ions which compete with high affinity bacterial transporters to import these essential nutrient metals (<xref ref-type="bibr" rid="bib36">Kehl-Fie and Skaar, 2010</xref>; <xref ref-type="bibr" rid="bib37">Kehl-Fie et al., 2011</xref>). In contrast to the proinflammatory role of S100A8/A9, regulatory functions in terms of hyporesponsiveness in phagocytes, resembling a classical endotoxin-induced tolerance, have also been described (<xref ref-type="bibr" rid="bib24">Freise et al., 2019</xref>).</p><p>In humans, S100A8/A9 is the most abundant alarmin in many clinically relevant diseases, and is closely associated with disease activity in rheumatoid arthritis (RA), inflammatory bowel disease, sepsis, cardiovascular diseases, multiple sclerosis, acute lung injury (ALI) and psoriasis (<xref ref-type="bibr" rid="bib21">Foell et al., 2004</xref>). Altered S100A8/A9 expression has also been found in different cancer types, including gastric, colorectal, breast, lung, prostate and liver cancer (<xref ref-type="bibr" rid="bib13">Cross et al., 2005</xref>). Despite the high expression in neutrophils and monocytes under inflammatory conditions, and the strong effects of S100A8 and S100A9 on disease activities, transcriptional mechanisms regulating these extreme dynamics of gene expression remain unclear. Identifying the mechanisms regulating <italic>S100a8</italic> and <italic>S100a9</italic> gene expression may open new insights into the pathological processes involving S100A8/A9 during inflammatory conditions.</p><p>So far, several potential transcription factors modulating <italic>S100a8</italic> and <italic>S100a9</italic> expression have been described (<xref ref-type="bibr" rid="bib43">Kuruto-Niwa et al., 1998</xref>; <xref ref-type="bibr" rid="bib26">Fujiu et al., 2011</xref>; <xref ref-type="bibr" rid="bib49">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="bib56">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="bib88">Yang et al., 2017</xref>), but their functional relevance remains unresolved. Many of the stated studies used malignant immortalized cell lines or even cell models whose homologous primary cells do not express these genes at all.</p><p>To overcome difficulties of artificial expression and malignant cell lines we used ER (estrogen-regulated) Hoxb8 cells, estrogen dependent transiently immortalized myeloid precursor cells that can be differentiated to primary monocytes and granulocytes upon estrogen-withdrawal (<xref ref-type="bibr" rid="bib79">Wang et al., 2006a</xref>), and show the physiologically high dynamics of S100A8 and S100A9 mRNA and protein expression during differentiation. In order to detect genes involved in the regulation of <italic>S100a8</italic> and <italic>S100a9</italic> expression in an unbiased manner, we used a mouse Genome-Scale CRISPR/Cas9 Knockout (GeCKO) library and screened for monocytes with reduced or absent S100A9 expression. We thereby identified the CCAAT/enhancer-binding protein-family member C/EBPδ as a direct transcriptional regulator of <italic>S100a8</italic> and <italic>S100a9</italic>. Furthermore, we found that the epigenetic factor JMJD3 contributes to <italic>S100a8</italic> and <italic>S100a9</italic> expression in monocytes by erasure of the repressive histone mark H3K27me<sub>3</sub> at <italic>S100a8</italic> and <italic>S100a9</italic> promoter regions. Moreover, we confirmed the biomedical relevance of this network a murine model of ALI and in specific monocyte subpopulations in a clinical cohort of patients with cardiovascular disease.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Genome-wide CRISPR/Cas9 knockout screen reveals C/EBPδ as a regulatory factor of S100A9 expression</title><p>To detect genes involved in the regulation of <italic>S100a8</italic> and <italic>S100a9</italic> expression, we established the mouse GeCKO lentiviral pooled library designed in Cas9-expressing ER-Hoxb8 cells. The used library contained a large mixture of CRISPR sgRNA constructs, where six gRNAs per target gene increase efficiency and enable the analysis of the molecular effects of many thousand genes in one experiment. After infection of Cas9-expressing ER-Hoxb8 precursor cells with CRISPR library lentiviral particles, the cells were differentiated for 3 days in the presence of GM-CSF to induce S100A8 and S100A9 expression. Because we hypothesized that the parallel S100A8 and S100A9 expression is based on a common regulatory mechanism, we assumed that screening of one of the two alarmins was sufficient in the first step. Therefore, cells with no or low S100A9 expression were selected by sorting and considered as hits, whereas the remaining cells functioned as reference cells. To exclude phenotypes that were S100A9<sup>low/neg</sup> due to general differentiation defects, we pre-gated for CD11b<sup>+</sup>Ly-6C<sup>+</sup> monocytes. DNA of sorted cell pools was purified and analysed by NGS (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Intracellular S100A9-FITC staining of precursor and differentiated Cas9 ER-Hoxb8 control monocytes was used as standard for definition of sorting gates. Differentiated Cas9-library ER-Hoxb8 monocytes showed a wider distribution among the gates, indicating the presence of S100A9<sup>low/neg</sup> expressing cells due to disruptions of regulatory genes caused by CRISPR/Cas9. A small amount of S100A9<sup>neg</sup> sorted cells were re-analysed by immunoblotting to validate S100A9 deficiency in this cell population (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Analysis of CRISPR KO library screen using the Model-based Analysis of Genome-wide CRISPR-Cas9 Knockout (MAGeCK) method (<xref ref-type="bibr" rid="bib52">Li et al., 2014</xref>) resulted in a list of genes for which the respective gRNAs were enriched in the hits sample. The highest number of three gRNAs was found within the top 20 hits targeted <italic>Cebpd</italic>, a gene encoding for a member of the CCAAT/enhancer-binding protein family, C/EBPδ. Other gene hits, namely <italic>Manea</italic>, <italic>Htr1f, Ifit3, Phf8, Hand1,</italic> and <italic>Casp4</italic>, were targeted by two gRNAs (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). From these, those genes known to be involved in gene regulation, such as the transcription factors <italic>Cebpd</italic> and <italic>Hand1</italic>, as well as the histone demethylase <italic>Phf8</italic>, were selected for validation. Another transcription factor in the top 20 hit list, <italic>Csrp1</italic>, was targeted by only one gRNA but was chosen for validation due to its known functions in gene regulatory mechanisms (<xref ref-type="bibr" rid="bib35">Kamar et al., 2017</xref>). Targeting <italic>Phf8</italic>, <italic>Hand1</italic>, and <italic>Csrp1</italic> only slightly influenced <italic>S100a8</italic> and <italic>S100a9</italic> expression, whereas C/EBPδ deficiency strongly decreased <italic>S100a8</italic> and <italic>S100a9</italic> levels in differentiated monocytes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Interestingly, none of the transcription factors previously reported to target <italic>S100a8</italic> and <italic>S100a9</italic> (<xref ref-type="bibr" rid="bib43">Kuruto-Niwa et al., 1998</xref>; <xref ref-type="bibr" rid="bib26">Fujiu et al., 2011</xref>; <xref ref-type="bibr" rid="bib49">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="bib56">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="bib88">Yang et al., 2017</xref>) were found within the hit list of our CRISPR KO library screen (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Nevertheless, to test the published candidate transcription factors ATF3, STAT3, KLF5, IRF7, and C/EBPβ for their effects on <italic>S100a8</italic> and <italic>S100a9</italic> regulation, we created single KO ER-Hoxb8 cell lines of each individual candidate transcription factor. Deficiency of none of the stated candidate transcription factors affects <italic>S100a8</italic> and <italic>S1009</italic> expression during monocyte differentiation, whereas C/EBPδ deficiency had a strong attenuating effect on <italic>S100a8</italic> and <italic>S100a9</italic> expression, as shown on day 2 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Genome-Scale CRISPR Knockout lentiviral pooled library screen to identify S100A9 regulators.</title><p>(<bold>A</bold>) For genome-wide screen, over 100,000 plasmids, each containing a guide RNA towards different early consecutive exons, were packaged into lentiviral particles. Cas9-expressing ER-Hoxb8 cells were pool-transduced, selected, and differentiated to induce S100A9 expression. Hits and reference cells were collected by sorting according to their phenotypes of interest. DNA of both samples was purified for next-generation sequencing and subsequent analysis. (<bold>B</bold>) Precursor and differentiated Cas9 and Cas9-library ER-Hoxb8 cells were stained intracellularly for S100A9 using a FITC-labelled antibody. Cas9-library ER-Hoxb8 day 3 monocytes with no or lower S100A9 expression were sorted as hits, the remaining cells served as reference cells. (<bold>C</bold>) Data was analysed using the Model-based Analysis of Genome-wide CRISPR-Cas9 Knockout (MAGeCK) software for identification of enriched guide RNAs in the hit sample. Corresponding genes were rank-ordered by robust rank aggregation (RRA) scores. The list states the top 20 genes according to RRA scores, arranged after the number of guides that are enriched in the hit sample. See also <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Gene summary of Model-based Analysis of Genome-wide CRISPR-Cas9 Knockout (MaGECK) analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-75594-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Relative <italic>S100a8</italic> and <italic>S100a9</italic> expression in differentiated single knockout (KO) ER-Hoxb8 monocytes.</title><p>Cell lines generated by CRISPR/Cas9 (A: PHF8, CSRP1, and HAND1 KO, dark grey bars = candidates from Genome-Scale CRISPR/Cas9 Knockout (GeCKO) screen, B: ATF3, STAT3, KLF5, IRF7, and C/EBPβ KO, light grey bars = candidates from previous studies) were compared to a non-targeting CRISPR/Cas9 control cell line. Cell lines generated from transgenic mice (C/EBPδ KO, black bars = hit from GeCKO screen) were compared to wildtype (WT) counterparts. All cells were differentiated to until day 2 or day 3 and relative <italic>S100a8</italic> and <italic>S100a9</italic> mRNA levels were analysed using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Red lines indicate relative <italic>s100</italic> level of controls (WT). Values are the means ± SEM of four experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 by two-tailed Student’s t test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Decreased <italic>S100a8</italic> and <italic>S100a9</italic> expression in C/EBPδ KO monocytes</title><p>We confirmed extraordinarily high dynamics of <italic>S100a8</italic> and <italic>S100a9</italic> expression during monocyte/macrophage differentiation. ER-Hoxb8-derived monocytes showed about 590-fold increase in <italic>S100a8</italic> mRNA expression and about 1800-fold increase of <italic>S100a9</italic> mRNA expression on day 2 compared to day 0 of differentiation. At day 5 the <italic>S100a8</italic> mRNA expression is already about 70-fold and the <italic>S100a9</italic> mRNA expression about 110-fold downregulated compared to day 2 of differentiation (<xref ref-type="fig" rid="fig2">Figure 2A, B</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>S100A8 and S100A9 expression in wildtype (WT) and C/EBPδ knockout (KO) monocytes.</title><p>(<bold>A</bold>) Relative <italic>S100a8</italic> and (<bold>B</bold>) <italic>S100a9</italic> mRNA level during differentiation of WT and C/EBPδ KO ER-Hoxb8 monocytes were measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR) (n=3–8). (<bold>C</bold>) S100A8/A9 concentrations in supernatant of differentiation day 4 of WT and C/EBPδ KO ER-Hoxb8 monocytes stimulated with 10 ng LPS for 4 hr or left untreated (n=3) were quantified using our in-house mouse S100A8/S100A9 sandwich enzyme-linked immunosorbent assay (ELISA) (n=6). (<bold>D</bold>) Relative <italic>S100a8</italic> and <italic>S100a9</italic> mRNA levels of bone marrow-derived mouse monocytes were measured using qRT-PCR (n=3). (<bold>E</bold>) Serum and (<bold>F</bold>) bronchoalveolar lavage fluid (BALF) of LPS- (WT: n=9, C/EBPδ KO: n=11) or NaCl-only (WT: n=6, C/EBPδ KO: n=3) exposed mice were harvested 4 hr after onset of lung inflammation and were analysed for S100A8/A9 expression, (<bold>G</bold>) for amount of recruited polymorphonuclear leukocytes (PMNs) and for (<bold>H</bold>) IL-1α, (<bold>I</bold>) IL-6, and (<bold>J</bold>) TNF-α production in BALF. Values are the means ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, by two-tailed Student’s t test (A–C, H–J) and by one-way ANOVA with Bonferroni’s correction (E–G). See also <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref> and <xref ref-type="fig" rid="fig2s2">2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title><italic>S100a8</italic>, <italic>S100a9,</italic> and <italic>Cebpd</italic> expression kinetics in ER-Hoxb8 cells.</title><p>(<bold>A</bold>) <italic>S100a8</italic> and <italic>S100a9</italic> mRNA levels were measured using qPCR (left, middle) and protein levels by using our in-house mouse S100A8/S100A9 sandwich enzyme-linked immunosorbent assay (ELISA) (right) in precursor and differentiated wildtype (WT) and C/EBPδ knockout (KO) ER-Hoxb8 neutrophils were analysed. <italic>Cebpd</italic> mRNA level was measured using qPCR in precursor and differentiated WT ER-Hoxb8 monocytes (<bold>B</bold>) and neutrophils (<bold>C</bold>). Values are the means ± SEM of three experiments. **p&lt;0.01, by Student’s t test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Baseline (NaCl) and LPS-induced cytokine production in sera of wildtype (WT) and C/EBPδ knockout (KO) mice.</title><p>Serum of LPS- (WT: n=9, C/EBPδ KO: n=11) or NaCl-only (WT: n=6, C/EBPδ KO: n=3) exposed mice was harvested 4 hr after onset of lung inflammation and was analysed for various cytokines using the bead-based immunoassay LEGENDplex. Values are the means ± SEM. p=0.057 by one-way ANOVA with Bonferroni’s correction.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig2-figsupp2-v2.tif"/></fig></fig-group><p>We confirmed the relevance of C/EBPδ for <italic>S100a8</italic> and <italic>S100a9</italic> expression by creating independent C/EBPδ-deficient ER-Hoxb8 cells from C/EBPδ KO mice. Not only on differentiation day 3, but already at the very beginning of differentiation, when <italic>S100a8</italic> and <italic>S100a9</italic> levels start to rise, C/EBPδ-deficient ER-Hoxb8 monocytes showed significantly reduced levels of both <italic>S100a8</italic> (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) and <italic>S100a9</italic> (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) mRNAs compared to wildtype (WT) controls. The same effect was detectable in C/EBPδ-deficient ER-Hoxb8 cells that were differentiated into the neutrophilic lineage (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Accordingly, <italic>Cebpd</italic> and <italic>S100a8</italic> and <italic>S100a9</italic> mRNAs were co-expressed in differentiating WT monocytes and neutrophils, supporting a mechanistic connection (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B, C</xref>). WT ER-Hoxb8 monocytes secreted significant S100A8/A9 protein amounts, whereas the supernatant of C/EBPδ KO cells contained up to 80% less S100A8/A9 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Accordingly, S<italic>100a8</italic> and <italic>S100a9</italic> expression was decreased upon C/EBPδ deletion in primary bone marrow-derived monocytes (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). To confirm that C/EBPδ deficiency affects alarmin expression and disease progression in vivo, we used a mouse model for acute lung inflammation. S100A8/A9 levels are locally increased in acute respiratory distress syndrome patients (<xref ref-type="bibr" rid="bib57">Lorenz et al., 2008</xref>) and have been shown to play a role in neutrophil recruitment during ALI in mice (<xref ref-type="bibr" rid="bib8">Chakraborty et al., 2017</xref>). Serum and bronchoalveolar lavage fluid (BALF) from LPS-exposed mice showed highly increased S100A8/A9 levels compared to control mice. In C/EBPδ KO mice, alarmin levels were systemically (serum) and locally (BALF) decreased compared to WT mice at baseline (NaCl) and after LPS exposure (<xref ref-type="fig" rid="fig2">Figure 2E, F</xref>), confirming our in vitro data. Accordingly, in BALF neutrophil recruitment (<xref ref-type="fig" rid="fig2">Figure 2G</xref>), as well as in IL-1α and IL-6, cytokine production was significantly decreased in LPS-exposed C/EBPδ KO mice in relation to WT littermates (TNF-α shows a similar trend, <xref ref-type="fig" rid="fig2">Figure 2H-J</xref>), which highlights the impact of S100A8/A9 on the disease outcome.</p></sec><sec id="s2-3"><title>Inflammatory capacities and differentiation kinetics are unaffected in C/EBPδ KO monocytes</title><p>Although the proinflammatory molecule S100A8/A9 was strongly reduced in the C/EBPδ KO monocytes, these cells exhibited no general alterations of inflammatory functions, indicating a rather specific effect on <italic>S100a8</italic> and <italic>S100a9</italic> regulation than a general attenuation of inflammatory signaling due to C/EBPδ deficiency. Phagocytosis capacities, examined by using FITC-coupled Latex Beads (<xref ref-type="fig" rid="fig3">Figure 3A, B</xref>) and by using <italic>Staphylococcus aureus</italic> (<xref ref-type="fig" rid="fig3">Figure 3C, D</xref>), were even elevated in C/EBPδ KO monocytes. These observations were accompanied by enhanced gene expression of phagocytosis-related PRRs, such as <italic>Ptx3</italic>, <italic>CD209a</italic>, and <italic>Cd14,</italic> in C/EBPδ KO monocytes (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A, B, D</xref>). ROS production was not influenced by C/EBPδ deficiency (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Moreover, analysis of differentiation kinetics revealed no exorbitant differences in the quantities of CD11b<sup>+</sup>Ly-6C<sup>+</sup> between WT and C/EBPδ KO cells, neither during differentiation of bone marrow-derived cells (BMCs) nor of ER-Hoxb8 cells (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). With regard to monocyte differentiation and polarization capacities, we tested the effect of C/EBPδ deficiency in primary bone marrow-derived mouse monocytes (BMDMs). Whereas expression of M<sub>1</sub>-monocyte associated markers, such as <italic>Tnfa, Il6, Inos, Cd86</italic>, and <italic>Il1b</italic>, was only slightly decreased in LPS- and IFN-γ-treated C/EBPδ KO monocytes in vitro (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>), M<sub>2</sub>-associated <italic>Il10</italic> expression was significantly decreased upon IL-4-stimulation in C/EBPδ KO cells confirming earlier results (<xref ref-type="bibr" rid="bib55">Liu et al., 2003</xref>). Expression of <italic>Cd163</italic> showed no significant effect in C/EBPδ KO cells (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>). Decreased IL-10 expression was also found in sera from LPS-treated and control C/EBPδ KO mice, whereas most other cytokine levels did not differ greatly between WT and C/EBPδ KO mice (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Functional properties of wildtype (WT) and C/EBPδ knockout (KO) ER-Hoxb8 monocytes.</title><p>Differentiated WT and C/EBPδ KO ER-Hoxb8 cells were incubated with green fluorescent latex beads (<bold>A, B</bold>) or with pHrodo Red <italic>Staphylococcus aureus</italic> Bioparticles Conjugate (<bold>C, D</bold>) for 2 hr at a ratio of 10 beads per cells. The phagocytosis was measured using flow cytometry. (<bold>A</bold>) Percentages of phagocytosis of ≥3 beads or (<bold>C</bold>) gMFI shifts of <italic>S. aureus</italic> -treated cells in relation to control cells were used for quantification. Representative histogram plots of Latex Beads- (<bold>B</bold>) and <italic>S. aureus</italic> Bioparticles- (<bold>D</bold>) mediated phagocytosis are presented. (<bold>B</bold>) Histogram plots, showing gates for phagocytosis of one (.), two (...), or ≥3 or more than three (…) beads. (<bold>E</bold>) Differentiated WT and C/EBPδ KO ER-Hoxb8 cells were treated with 10 nM PMA for 15 min and 15 µM DHR123 to measure oxidative burst was measured using DHR123. The fluorescence of the cells was measured using flow cytometry. Relative ROS production as = gMFI shifts of PMA-treated cells in relation to non-treated cells is shown. (<bold>F</bold>) Proportion of CD11b<sup>+</sup>Ly-6C<sup>+</sup> cells during differentiation of bone marrow cells (BMCs) and ER-Hoxb8 cells was analysed using flow cytometry. Values are the means ± SEM of three to four experiments. *p&lt;0.05, **p&lt;0.01 by two-tailed Student’s t test. See also <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref> and <xref ref-type="fig" rid="fig3s2">2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Differential expression of phagocytosis-related genes in wildtype (WT) and C/EBPδ knockout (KO) monocytes.</title><p>(<bold>A</bold>) <italic>Ptx3</italic>, (<bold>B</bold>) <italic>Cd209a</italic>, (<bold>C</bold>) <italic>Msr1</italic>, and (<bold>D</bold>) <italic>Cd14</italic> mRNA levels were analysed using qPCR in differentiated WT and C/EBPδ KO ER<bold>-</bold>Hoxb8 monocytes. Values are the means ± SEM of three to five experiments. *p&lt;0.05, by two-tailed Student’s t test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Effect of C/EBPδ deletion on polarization of bone marrow-derived monocytes.</title><p>The mRNA levels of genes (<bold>A</bold>) associated with M<sub>1</sub>-polarization (<italic>Tnfa</italic>, <italic>Il6</italic>, <italic>Inos</italic>, <italic>Cd86</italic>, and <italic>Il1b</italic>) and (<bold>B</bold>) associated with M<sub>2</sub>-polarization (<italic>Il10</italic> and <italic>Cd163</italic>) were analysed. For this, wildtype (WT) and C/EBPδ knockout (KO) bone marrow-derived mouse monocytes (BMDMs) were either stimulated for 24 hr with 50 ng/ml IFN-γ and 10 ng/ml LPS (<bold>M<sub>1</sub></bold>), with 20 n/ml IL-4 (<bold>M<sub>2</sub></bold>) or left untreated (<bold>M<sub>0</sub></bold>). Values are the means ± SEM of three experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant, by one-way ANOVA with Bonferroni’s correction.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig3-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Enhanced C/EBPδ expression induces <italic>S100a8</italic> and <italic>S100a9</italic> expression</title><p>To test the impact of C/EBPδ induction on <italic>S100</italic> alarmin expression, we infected C/EBPδ-deficient ER-Hoxb8 cells with lentiviral particles carrying a Tet-On system for doxycycline-inducible 3xFlag-C/EBPδ expression (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Doxycycline treatment led to expression of the fusion protein 3xFlag-C/EBPδ, as revealed by western blot analysis (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) and by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in comparison to C/EBPδ-deficient cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Induction of 3xFlag-C/EBPδ upon doxycycline treatment led to increased <italic>S100a8</italic> and <italic>S100a9</italic> mRNA levels. C<italic>ebpd</italic>, <italic>S100a8</italic>, and <italic>S100a9</italic> mRNA levels in doxycycline-treated TRE_3xFlag-C/EBPδ cells were comparable to WT cells at the same differentiation stage (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), demonstrating a positive effect of C/EBPδ expression on <italic>S100a8</italic> and <italic>S100a9</italic> regulation. KO of ATF3, a known regulatory attenuator of <italic>Cebpd</italic> expression (<xref ref-type="bibr" rid="bib54">Litvak et al., 2009</xref>), in ER-Hoxb8 monocytes led to <italic>S100a8</italic> and <italic>S100a9</italic> overexpression (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>), especially during early stages of differentiation. ATF3 KO cells showed significantly elevated <italic>cebpd</italic> level, indicating a C/EBPδ-mediated effect on the expression of <italic>S100a8</italic> and <italic>S100a9</italic> (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). In the next step, we created FBXW7-deficient monocytes. FBXW7 is another well-known attenuator of C/EBPδ expression (<xref ref-type="bibr" rid="bib4">Balamurugan et al., 2013</xref>). Lack of this antagonist resulted in an even higher overexpression of <italic>S100a8</italic> and <italic>S100a9</italic> (<xref ref-type="fig" rid="fig4">Figure 4G</xref>) with huge increases of <italic>Cebpd</italic> levels (<xref ref-type="fig" rid="fig4">Figure 4H</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>S100a8</italic> and <italic>S100a9</italic> expression in differentiated ER-Hoxb8 cells is dependent on C/EBPδ abundancy.</title><p>(<bold>A</bold>) Tet-On construct of inducible 3xFlag-C/EBPδ expression due to constitutively expressed rtTA (reverse tetracycline-controlled transactivator) that binds to TRE promoter upon doxycycline treatment was transduced into C/EBPδ knockout (KO) ER-Hoxb8 cells. (<bold>B</bold>) Induction of 3xFlag-C/EBPδ upon doxycycline treatment (2 µg/ml, 24 hr) was analysed by western blot and (<bold>C</bold>) quantitative reverse transcription polymerase chain reaction (qRT-PCR) in comparison to untreated cells. (<bold>D</bold>) Induction of 3xFlag-C/EBPδ was also analysed by qRT-PCR (<italic>Cebpd</italic>), as well as expression of <italic>S100a8</italic> and <italic>S100a9</italic> mRNAs, in untreated and dox-treated C/EBPδ KO TRE_3xFlag-C/EBPδ monocytes and in comparison to wildtype (WT) and C/EBPδ KO monocytes on differentiation day 1 (n=3). (<bold>E, G</bold>) <italic>S100a8</italic> and <italic>S100a9</italic>, (<bold>F, H</bold>) and <italic>Cebpd</italic> mRNA levels were measured using qRT-PCR in precursor and differentiated WT and ATF3 KO (<bold>E, F</bold>) and in WT and FBXW7 KO (<bold>G, H</bold>) ER-Hoxb8 monocytes (n=3–4). Values are the means ± SEM. *p&lt;0.05, **p&lt;0.01, by one-way ANOVA with Bonferroni’s correction (<bold>D</bold>) and by two-tailed Student’s t test (E–H).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig4-v2.tif"/></fig><p>To confirm the biomedical relevance of the identified molecular network, we analysed the expression of these genes in peripheral blood mononuclear cells (PBMCs) and monocyte subpopulations of a subset of participants in the BioNRW Study (<xref ref-type="bibr" rid="bib83">Witten et al., 2022</xref>). Here, we found upregulation of <italic>S100A8</italic>, <italic>S100A9</italic>, and <italic>CEBPD</italic> in PBMCs of stable coronary artery disease/myocardial infarction (sCAD/MI) cases, compared against controls (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), together with a positive correlation of <italic>S100A8</italic> and <italic>S100A9</italic> expression with that of <italic>CEBPD</italic> in these cells (<xref ref-type="fig" rid="fig5">Figure 5B, C</xref>). Moreover, there was also significant upregulation of these three genes specifically in classical monocytes, compared to intermediate and non-classical monocyte subpopulations (<xref ref-type="fig" rid="fig5">Figure 5D, E</xref>, for further comparisons, see <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). A strong positive correlation between the expression of <italic>S100A8</italic> and <italic>S100A9</italic> and <italic>CEBPD</italic> in these monocyte subpopulations was found, suggesting that the expression of these genes is mainly associated with the subset of proinflammatory monocytes. Interestingly, we also found significant albeit milder, negative correlations between the expression of <italic>CEBPD</italic> and its antagonists <italic>FBXW7</italic> and <italic>ATF3</italic> in monocytes (<xref ref-type="fig" rid="fig5">Figure 5F, G</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title><italic>CEBPD</italic> expression positively correlates with <italic>S100A8</italic> and <italic>S100A9</italic> expression in proinflammatory monocytes of myocardial infarction/stable coronary artery disease (MI/sCAD) patients.</title><p>(<bold>A</bold>) Gene expression changes detected by RNA-sequencing (RNA-seq) in peripheral blood mononuclear cells (PBMCs) of BioNRW participants (n=72, sCAD/MI vs. Ctrl). LFC = log2 fold change, SE = standard error, and adj.p = adjusted p-value. (<bold>B</bold>) Pearson correlation coefficient = r, p-value = p in PBMCs and (<bold>C</bold>) corresponding correlation matrix. (<bold>D</bold>) Gene expression changes of <italic>CEBPD</italic>, <italic>S100A8</italic>, <italic>S100A9</italic>, <italic>ATF3</italic>, and <italic>FBXW7</italic> detected by RNA-seq in monocyte subpopulations of BioNRW participants (n=26, from three individuals in each of the sCAD, MI, and Ctrl diagnostic groups). (<bold>E</bold>) Hierarchical clustering of <italic>S100A8</italic>-, <italic>S100A9</italic>-, and <italic>CEBPD</italic> normalized counts (using Euclidean distance metric with complete linkage). Shown are classical (1), intermediate (2), and non-classical (3) monocytes of healthy donors (Ctrl), MI, and sCAD patients. (<bold>F</bold>) Pearson correlation coefficient = r, p-value = p in monocytes and (<bold>G</bold>) corresponding correlation matrix. See also <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Expression changes in the BioNRW monocytes dataset (RNA-sequencing [RNA-seq], n=26).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-75594-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig5-v2.tif"/></fig></sec><sec id="s2-5"><title>C/EBPδ-binding sites within <italic>S100a8</italic> and <italic>S100a9</italic> promoter regions</title><p>Chromatin immunoprecipitation (ChIP) revealed 3xFlag-C/EBPδ binding on <italic>S100a8</italic> and <italic>S100a9</italic> promoter regions just before or within the predicted enhancers (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Co-transfection of HEK293T cells with GFP-expressing <italic>s100</italic> reporter vectors, together with doxycycline-inducible 3xFlag-C/EBPδ vector (TRE_3xFlag-C/EBPδ) or its backbone lacking the 3xFlag-C/EBPδ construct (TRE_ctrl), was performed to further examine specific C/EBPδ binding (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Doxycycline treatment resulted in 3xFlag-C/EBPδ protein expression after 24 hr post-transfection in 3xFlag-C/EBPδ vector transfected cells (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Transfection of either <italic>S100a8</italic> reporter construct (<xref ref-type="fig" rid="fig6">Figure 6D</xref>) or <italic>S100a9</italic> reporter construct (<xref ref-type="fig" rid="fig6">Figure 6F</xref>) together with 3xFlag-C/EBPδ vector led to enhanced GFP expression upon doxycycline treatment in comparison to co-transfection with backbone plasmid (TRE_ctrl). Next, we modified predicted C/EBP-binding sites on <italic>S100</italic> promoters by mutagenesis of the corresponding vectors. Again, co-transfection of mutated <italic>S100</italic> reporter vectors and doxycycline-dependent 3xFlag-C/EBPδ vector was performed to analyse the relevance of specific C/EBPδ-binding sites. Two sites within the <italic>S100a8</italic> promoter region, stated as site 2 and site 3 (<xref ref-type="fig" rid="fig6">Figure 6E</xref>), and one within the <italic>S100a9</italic> promoter region, stated as site 4 (<xref ref-type="fig" rid="fig6">Figure 6G</xref>), caused a reduced or absent GFP expression upon co-transfection when deleted. These binding sites, in turn, were located within the <italic>S100a8</italic> and <italic>S100a9</italic> promoter regions where C/EBPδ binding was confirmed by ChIP (<xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>C/EBPδ binds to regions within the <italic>S100a8</italic> and <italic>S100a9</italic> promoters.</title><p>(<bold>A</bold>) Chromatin immunoprecipitation was performed in untreated (-) and dox-treated (+dox) TRE_3xFlag-C/EBPδ monocytes on differentiation day 1 using a Flag-antibody. Purified DNA was analysed using primer pairs flanking different <italic>S100a8</italic> and <italic>S100a9</italic> promoter and intronic regions and a negative control primer pair flanking a random genomic region (n=3). (<bold>B</bold>) Co-transfection of vectors carrying constructs for GFP under the <italic>S100a8</italic> or <italic>S100a9</italic> promoter (reporter), together with the doxycycline-dependent 3xFlag-C/EBPδ expression cassette (TRE_3xFlag-C/EBPδ) or a corresponding control vector lacking the 3xFlag-C/EBPδ expression cassette (TRE_ctrl) in HEK293T cells, was performed. (<bold>C</bold>) Induction of 3xFlag-C/EBPδ upon doxycycline treatment (2 µg/ml, 24 hr) was analysed by western blot. Representative dot plots from flow cytometry analysis show GFP<sup>+</sup> gates of co-transfected HEK293T cells, either using TRE_3xFlag-C/EBPδ or TRE_ctrl together with <italic>S100a8</italic> reporter (<bold>D</bold>) and with <italic>S100a9</italic> reporter (<bold>F</bold>) upon doxycycline treatment (2 µg/ml, 24 hr). Co-transfection of TRE_3xFlag-C/EBPδ and <italic>S100a8</italic> (<bold>E</bold>) and <italic>S100a9</italic> (<bold>G</bold>) reporter plasmids carrying different mutated possible binding sites was performed, analysed 24 hr post-transfection and compared to co-transfection of TRE_ctrl and <italic>S100</italic> reporter plasmid activities. Suggested C/EBP-binding sites targeted by depletion are indicated by nucleic acids marked in red (n=4–5). Values are the means ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant, by two-tailed Student’s t test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig6-v2.tif"/></fig></sec><sec id="s2-6"><title>Epigenetic landscape on <italic>S100</italic> promoter regions reflects <italic>S100a8</italic> and <italic>S100a9</italic> expression in monocytes</title><p>Regulation of gene expression relies on variable factors; among these are chromatin structure and epigenetic features. To measure changes in chromatin accessibility in monocytic progenitors and in <italic>S100a8-</italic> and <italic>S100a9</italic>-expressing monocytes, we performed ATAC-seq of precursor and differentiated WT and C/EBPδ KO ER-Hoxb8 cells. This revealed over 1000 regions with differential peaks in all comparisons (<xref ref-type="fig" rid="fig7">Figure 7A</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Among the regions with significantly higher ATAC-seq reads in differentiated samples at day 3 of WT cells were the <italic>S100a8</italic> and <italic>S100a9</italic> promoter and enhancer locations. Interestingly, within these regions chromatin accessibility was significantly decreased in C/EBPδ KO in comparison to WT cells at day 3 of differentiation (<xref ref-type="fig" rid="fig7">Figure 7B, C</xref>). Consistent with the changes in chromatin accessibility at <italic>S100</italic> promoter regions during differentiation, we also found changes in histone marks by ChIP. H3K27 acetylation (H3K27ac), a marker for active transcription, was increased at differentiation day 3 in monocytes over precursor cells at <italic>S100a8</italic> (<xref ref-type="fig" rid="fig7">Figure 7D</xref>) and <italic>S100a9</italic> loci (<xref ref-type="fig" rid="fig7">Figure 7E</xref>) in both, WT and C/EBPδ KO cells. In contrast, tri-methylated H3K27 (H3K27me<sub>3</sub>), associated with gene silencing, was overrepresented in precursor cells over differentiated cells at the same loci in WT cells, whereas H3K27me<sub>3</sub> marks did not decrease over the course of differentiation in C/EBPδ KO cells. Accordingly, tri-methylated H3K27 was increased in C/EBPδ KO monocytes, compared to the WT counterparts (<xref ref-type="fig" rid="fig7">Figure 7F, G</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Analysis of chromatin accessibility and epigenetic features within <italic>S100a8</italic> and <italic>S100a9</italic> promoter regions.</title><p>Assay for transposase-accessible chromatin using sequencing (ATAC-seq) was executed in precursor (day 0=d0) and differentiated (day 3=d3) wildtype (WT) and C/EBPδ knockout (KO) (KO) ER-Hoxb8 monocytes. (<bold>A</bold>) Differential peak analysis between all conditions was performed (n=3). (<bold>B</bold>) Combined gene tracks showing ATAC-seq reads of precursor (day 0) and differentiated (day 3) WT and C/EBPδ KO cells at the <italic>S100a8</italic> and <italic>S100a9</italic> gene regions. (<bold>C</bold>) Differential accessibility at <italic>S100a8</italic> and <italic>S100a9</italic> loci was analysed for all comparisons. Chromatin immunoprecipitation was performed using anti-H3K27ac (<bold>D, E</bold>), anti-H3K27me3 (<bold>F, G</bold>) in chromatin of precursor (day 0) and differentiated (day 3) WT and C/EBPδ KO (KO) ER-Hoxb8 monocytes. Purified DNA was analysed using primer pairs flanking different <italic>S100a8</italic> (<bold>D, F</bold>) and <italic>S100a9</italic> (<bold>E, G</bold>) promoter regions (n=3–6). N-folds are based on percent of input values of respective day 0 ChIP-PCR samples. Values are the means ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant, by one-way ANOVA with Bonferroni’s correction. See also <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Differential peak analysis based on assay for transposase-accessible chromatin using sequencing (ATAC-seq) data of wildtype (WT) and C/EBPδ knockout (KO) day 0 and day 3 ER-Hoxb8 cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-75594-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Differential peak analysis based on assay for transposase-accessible chromatin using sequencing (ATAC-seq) data of wildtype (WT) and C/EBPδ knockout (KO) day 0 and day 3 ER-Hoxb8 cells.</title><p>Volcano plots show differentially accessible regions between day 3 and day 0 (<bold>A</bold>) in WT and (<bold>B</bold>) in C/EBPδ KO cells, and between C/EBPδ KO and WT (<bold>C</bold>) at day 0 and (<bold>D</bold>) at day 3. NS = not significant; FC = fold change.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig7-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-7"><title>The histone demethylase JMJD3 drives <italic>S100a8</italic> and <italic>S100a9</italic> expression in dependency of C/EBPδ</title><p>Decreased <italic>S100a8</italic> and <italic>S100a9</italic> expression in C/EBPδ-deficient day 3 monocytes was mirrored in the epigenetic landscape by only slightly decreased H3K27ac level, but highly increased H3K27me<sub>3</sub> level at <italic>S100</italic> promoter regions. Erasure of tri-methylation and di-methylation at H3K27 is known to be catalysed by the histone demethylase JMJD3 (JmjC Domain-Containing Protein 3) (<xref ref-type="bibr" rid="bib84">Xiang et al., 2007</xref>). We found decreased expression of <italic>Jmjd3</italic> in differentiated C/EBPδ KO monocytes, compared to WT cells at the same stage (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Further, we used the potent JMJD3 inhibitor GSK-J4 (<xref ref-type="bibr" rid="bib41">Kruidenier et al., 2012</xref>) to block H3K27 demethylation in differentiating ER-Hobx8 cells, and discovered significantly decreased <italic>S100a8</italic> and <italic>S100a9</italic> expression in GSK-J4-treated WT cells (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). These mRNA quantities were comparable to untreated C/EBPδ-deficient monocytes, whereas the effects on <italic>S100a8</italic> and <italic>S100a9</italic> expression in GSK-J4-treated C/EBPδ-deficient monocytes, compared to the untreated counterparts, were negligible (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). These effects of GSK-J4 on <italic>S100a8</italic> and <italic>S100a9</italic> expression are in line with increased H3K27me<sub>3</sub> marks in GSK-J4-treated WT monocytes, compared to untreated WT cells on both, <italic>S100a8</italic> (<xref ref-type="fig" rid="fig8">Figure 8C</xref>) and <italic>S100a9</italic> (<xref ref-type="fig" rid="fig8">Figure 8D</xref>) promoter regions.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>JMJD3-mediated demethylation of H3K27me<sub>3</sub> is crucial for <italic>S100a8</italic> and <italic>S100a9</italic> expression.</title><p>(<bold>A</bold>) <italic>Jmjd3</italic> mRNA levels of precursor and differentiated wildtype (WT) and C/EBPδ knockout (KO) ER-Hoxb8 cells were analysed using quantitative reverse transcription polymerase chain reaction (qRT-PCR) (n=3). (<bold>B</bold>) WT and C/EBPδ KO ER-Hoxb8 cells were treated with 5 µM GSK-J4 for 3 days during differentiation and <italic>S100a8</italic> and <italic>S100a9</italic> mRNA levels were analysed using qRT-PCR (n=5). Chromatin immunoprecipitation was performed using anti-H3K27me<sub>3</sub> and appropriate IgG control antibodies in chromatin of vehicle controls (-) and treated (+GSK-J4) WT and C/EBPδ KO (KO) ER-Hoxb8 monocytes. Purified DNA was analysed using primer pairs flanking different <italic>S100a8</italic> (<bold>C</bold>) and <italic>S100a9</italic> (<bold>D</bold>) promoter regions (n=3–5). Values are the means ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant, by one-way ANOVA with Bonferroni’s correction (<bold>A, B</bold>) or by two-tailed Student’s t test in comparison to WT (-) (<bold>C, D</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-75594-fig8-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The ER-Hoxb8 cell system serves as a substitute for murine primary cells of myeloid origin that can be differentiated into phagocytes, such as monocytes and neutrophils. It reflects reliably the differentiation of myeloid progenitor cells to bone marrow-derived monocytes and macrophages. Due to the high expression of S100A8 and S100A9 in the early days of culture around day 3, we describe these stage as monocytes, later days of differentiation with no or low expression of these S100 proteins as macrophages in analogy to the human system. This system allows comparison with in vitro differentiated primary cells (<xref ref-type="bibr" rid="bib79">Wang et al., 2006a</xref>) and, therefore, provides an experimental cell model for analysis of S100A8 and S100A9 expression. Although the alarmins are regarded as key factors in various inflammatory conditions (<xref ref-type="bibr" rid="bib22">Foell and Roth, 2004</xref>), cancer types (<xref ref-type="bibr" rid="bib13">Cross et al., 2005</xref>), and cardiovascular diseases (<xref ref-type="bibr" rid="bib23">Frangogiannis, 2019</xref>), little is known about their transcriptional regulation. The serum concentrations of alarmins correlate with disease severity and activity and, hence, they are reliable biomarkers for monitoring several inflammatory diseases (<xref ref-type="bibr" rid="bib21">Foell et al., 2004</xref>; <xref ref-type="bibr" rid="bib19">Ehrchen et al., 2009</xref>). The expression levels of <italic>S100a8</italic> and <italic>S100a9</italic> differ extremely during myeloid differentiation and the promoters of their genes represent probably one of the most dynamic regulatory elements in the myeloid lineage. Whereas both proteins are completely absent in myeloid precursor cells, they are highly expressed in monocytes and neutrophils, which suggests that highly dynamic regulatory mechanisms drive <italic>S100a8</italic> and <italic>S100a9</italic> expression.</p><p>The CRISPR/Cas9-mediated KO screening approach based on a lentiviral pooled library has been used so far to investigate various mechanisms, such as immunity-related pathways and cancer-modulating events (<xref ref-type="bibr" rid="bib44">Kweon and Kim, 2018</xref>). In this study, our unbiased genome-wide screening approach allowed the identification of C/EBPδ as a factor involved in S100A9 regulation during murine monocyte differentiation. We further focused our investigations on <italic>Cebpd</italic> because this gene was in the top list of the robust rank aggregation (RRA) scores and showed the highest numbers of guide RNAs with efficient effects on S100A9 expression in our screening. This redundancy of independent parameters helped to distinguish true positive from false positive hits. Furthermore, a robust phenotype-of-interest, such as a clear S100A9 protein signal at day 3 of monocyte differentiation, allowed reliable negative selection in Cas9-library monocytes. Selection of remaining cells served as a reference control to distinguish true from false positives. The specificity of our selection procedure was confirmed at the protein level by western blot analysis of sorted cell populations. CRISPR/Cas9-based functional genomic screening has been reported to be highly specific, thereby causing fewer cases of false positives in direct comparison with knockdown analysis by RNA interference (<xref ref-type="bibr" rid="bib68">Shalem et al., 2014</xref>). We were now able to identify a novel regulator of S100A8 and S100A9 using this unbiased method. By pre-gating on CD11b<sup>+</sup>Ly-6C<sup>+</sup> monocytes, we revealed C/EBPδ as a specific and differentiation-independent regulator of S100A8 and S100A9, excluding pathways linked to general functions or development of phagocytes. Re-analysis of S100A9 expression by immunoblotting of sorted cell populations verified the gates set (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). However, validation of four candidate genes from our hit list demonstrates the limitation of the CRISPR screening system. Not every targeted hit, such as <italic>Phf8</italic>, <italic>Hand1</italic>, and <italic>Csrp1</italic>, showed a prominent effect on <italic>S100a8</italic> and <italic>S100a9</italic> expression. Possibly, the slight differences are rather due to indirect effects on <italic>S100</italic> expression than due to deficiency of actual direct regulators. Another interesting gene within our top 20 hit list is the transcription factor <italic>creb1</italic> (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) that is known to mediate cytokine signaling at least in human neutrophils and could therefore be tested for <italic>S100a8</italic> and <italic>S100a9</italic> regulation in future experiments (<xref ref-type="bibr" rid="bib60">Mayer et al., 2013</xref>). Known regulators of S100A8 and S100A9 that are also essential for general differentiation, such as PU.1 (<xref ref-type="bibr" rid="bib86">Xu et al., 2021</xref>), were very likely excluded due to our monocyte pre-gating strategy. Our data indicate that this screening technique seems not optimal enough to identify all factors of an interrelated regulatory protein complex, but it is sufficient for unbiased detection of single factors for gene regulation, as shown in our study.</p><p>We confirmed that the transcription factor C/EBPδ is a direct regulator of S100A8 and S100A9 in murine monocytes using independent approaches. <italic>Cebpd,</italic> and <italic>S100a8</italic> and <italic>S100a9</italic> were co-expressed in differentiating monocytes, and induction of C/EBPδ clearly showed that the expression of <italic>S100a8</italic> and <italic>S100a9</italic> was upregulated by the presence of C/EBPδ. This evidence was further supported by increased <italic>S100a8</italic> and <italic>S100a9</italic> levels caused by deletion of ATF3 and FBXW7, which are natural inhibitors of C/EBPδ. There is a parallel decrease of <italic>Cebpd</italic>, and <italic>S100a8</italic> and <italic>S100a9</italic> expression during later stages of monocyte/macrophage differentiation which may point to a functional relation of C/EBPδ expression and downregulation of <italic>S100</italic> expression as well. However, the late expression kinetics of <italic>S100a8</italic> and <italic>S100a9</italic> in WT and C/EBPδ KO cells clearly point to the presence of additional relevant factors which were not addressed by our screening approach.</p><p>The specificity of our approach was further confirmed by the fact that deficiency of several transcription factors, such as STAT3, KLF5, IRF7, and C/EBPβ, described as S100A8 and S100A9 regulators in previous studies (<xref ref-type="bibr" rid="bib43">Kuruto-Niwa et al., 1998</xref>; <xref ref-type="bibr" rid="bib26">Fujiu et al., 2011</xref>; <xref ref-type="bibr" rid="bib49">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="bib56">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="bib88">Yang et al., 2017</xref>), did neither affect <italic>S100a8</italic> and <italic>S100a9</italic> expression in our ER-Hoxb8 monocytes, nor were these listed as gene hits in our CRISPR/Cas9-mediated KO screening approach. Our ChIP data clearly showed that C/EBPδ specifically binds within <italic>S100a8</italic> and <italic>S100a9</italic> promoter regions. Co-transfection of an inducible C/EBPδ construct and <italic>S100a8</italic> and <italic>S100a9</italic> reporter constructs not only demonstrated <italic>S100</italic> promoter activation due to C/EBPδ expression, but also revealed functional relevance of specific binding sites, via promoter bashing, that are located exactly within the stated promoter regions. The two DNA motifs for specific C/EBPδ responses on the <italic>S100a8</italic> promoter regions did not share the core sequence 5’-C/G GCAAT-3’ that we found within the <italic>S100a9</italic> promoter region in our study. The latter has been described in three other promoters, the human <italic>PPARG2</italic> promoter (<xref ref-type="bibr" rid="bib45">Lai et al., 2008</xref>), the murine and human <italic>CEBPD</italic> promoter itself (<xref ref-type="bibr" rid="bib81">Wang et al., 2021</xref>), and the human <italic>COX2</italic> promoter (<xref ref-type="bibr" rid="bib80">Wang et al., 2006b</xref>). We were able to show that the functionally relevant C/EBPδ-binding sites within the <italic>S100</italic> promoters lie within genome regions which switch from closed to open chromatin states during monocyte differentiation, and concomitant induction of <italic>S100</italic> expression as examined by ATAC-seq.</p><p>Our chromatin accessibility data on <italic>S100a8</italic> and <italic>S100a9</italic> promoter regions reflected active <italic>S100a8 and S100a9</italic> transcription on day 3 cells and accurately mirrored decreased <italic>S100</italic> expression of C/EBPδ KO monocytes in relation to WT counterparts. These observations were again reflected and supported by the characterization of the epigenetic landscape using H3K27ac and H3K27me<sub>3</sub> marks. The fact that H3K27me<sub>3</sub> marks were strongly decreased in WT monocytes, but not in precursors or C/EBPδ-deficient monocytes, showed the indispensability of H3K27 demethylation for <italic>S100a8</italic> and <italic>S100a9</italic> expression. Moreover, our data demonstrated that the Jumonji C family histone demethylase JMJD3 regulates <italic>S100a8</italic> and <italic>S100a9</italic> expression by erasure of H3K27me<sub>3</sub> in dependency of C/EBPδ, which was confirmed by GSK-J4-mediated inhibition of JMJD3 activities. Neither a link of C/EBPδ nor of S100A8/A9 and JMJD3 has been published yet. It has been shown that histone demethylase activities of recombinant JMJD3 on mono-nucleosome substrates is relatively low in contrast to higher activities on bulk histones (<xref ref-type="bibr" rid="bib46">Lan et al., 2007</xref>), suggesting that further factors, such as C/EBPδ, are involved in chromatin binding. Several studies highlight JMJD3 as a regulator of innate immune responses, especially via NF-κB-mediated inflammation in macrophages (<xref ref-type="bibr" rid="bib63">Na et al., 2016</xref>; <xref ref-type="bibr" rid="bib64">Na et al., 2017</xref>; <xref ref-type="bibr" rid="bib15">Davis et al., 2020</xref>). Accordingly, knockdown of JMJD3 affected mainly inflammatory response networks in monocytic THP-1 cells (<xref ref-type="bibr" rid="bib14">Das et al., 2012</xref>) and blocked activation of the NLRP3 inflammasome in bone marrow-derived macrophages (<xref ref-type="bibr" rid="bib32">Huang et al., 2020</xref>). GSK-J4 treatment of mice attenuated disease progression and inflammatory activities in several mouse models for inflammatory diseases, such as arthritis (<xref ref-type="bibr" rid="bib33">Jia et al., 2018</xref>), colitis (<xref ref-type="bibr" rid="bib32">Huang et al., 2020</xref>), and EAE (experimental autoimmune encephalomyelitis) (<xref ref-type="bibr" rid="bib17">Doñas et al., 2016</xref>). Accordingly, GSK-J4 treatment of our ER-Hoxb8 monocytes reduced expression of the proinflammatory alarmins <italic>S100a8</italic> and <italic>S100a9</italic>, which have been shown to drive the inflammatory process of arthritis (<xref ref-type="bibr" rid="bib74">van Lent et al., 2012</xref>). With our study, we have taken a step forward to uncover the role of epigenetic features on <italic>S100a8</italic> and <italic>S100a9</italic> expression and, thereby, on inflammatory conditions in murine monocytes.</p><p>We were also able to demonstrate an association of <italic>CEBPD</italic>, and <italic>S100A8</italic> and <italic>S100A9</italic> expression in the context of human cardiovascular disease. The expression of these molecules shows a significant positive correlation not only to each other but also to the manifestation of sCAD and MI in patient-derived PBMCs. Moreover, expression of <italic>CEBPD</italic>, <italic>S100A8</italic> and <italic>S100A9</italic> showed an even stronger association with classical, proinflammatory monocytes (CD14<sup>++</sup>CD16<sup>-</sup>), compared to non-classical (CD14<sup>+</sup>CD16<sup>++</sup>) and intermediate (CD14<sup>++</sup>CD16<sup>+</sup>) monocytes. The endogenous antagonists of C/EBPδ, ATF3 and especially FBXW7, showed a negative correlation of their expression pattern in these monocyte subpopulations. Interestingly, inflammatory monocytes with phagocytic and proteolytic activities have been reported to show an early peak at infarct sites, which are followed by infiltration of non-classical, anti-inflammatory monocytes (<xref ref-type="bibr" rid="bib65">Nahrendorf et al., 2007</xref>; <xref ref-type="bibr" rid="bib18">Dutta and Nahrendorf, 2015</xref>). Genetic deletion of S100A8/A9 was reported to attenuate MI and improve cardiac function in murine models. In contrast, overexpression of <italic>S100a9</italic> in mice increased infarct size and mortality, and treatment with recombinant S100 proteins raised influx of immune cells into the infarct area (<xref ref-type="bibr" rid="bib53">Li et al., 2019</xref>; <xref ref-type="bibr" rid="bib70">Sreejit et al., 2020</xref>). Moreover, serum concentrations of S100A8/A9 are known to be highly sensitive and prognostic markers for myocardial injury (<xref ref-type="bibr" rid="bib3">Aydin et al., 2019</xref>). Taken together, these data indicate that the C/EBPδ-S100 alarmin axis drives a clinically relevant pathomechanism in cardiovascular disease and probably other inflammation-driven conditions.</p><p>There are several published reports suggesting a biomedical relevance of the link between the C/EBPδ and the S100A8/A9 alarmin under other inflammatory conditions as well. For example, C/EBPδ has been shown to play a role in the pathogenesis of psoriasis (<xref ref-type="bibr" rid="bib47">Lan et al., 2020</xref>) and in acute inflammatory signaling by regulating COX-2 (<xref ref-type="bibr" rid="bib78">Wadleigh et al., 2000</xref>), IL-6 (<xref ref-type="bibr" rid="bib54">Litvak et al., 2009</xref>), and TLR4 (<xref ref-type="bibr" rid="bib4">Balamurugan et al., 2013</xref>). Analysis of the genome-wide transcription pattern of monocytes revealed <italic>IL6</italic> as the top gene induced by S100 alarmin stimulation via interaction with TLR4 (<xref ref-type="bibr" rid="bib20">Fassl et al., 2015</xref>), and targeted deletion of S100A9 ameliorated inflammation in a murine psoriasis model (<xref ref-type="bibr" rid="bib89">Zenz et al., 2008</xref>). Additionally, C/EBPδ levels were elevated in mouse models and patients of Alzheimer’s disease (AD) (<xref ref-type="bibr" rid="bib51">Li et al., 2004</xref>; <xref ref-type="bibr" rid="bib40">Ko et al., 2012</xref>) and RA (<xref ref-type="bibr" rid="bib66">Nishioka et al., 2000</xref>; <xref ref-type="bibr" rid="bib9">Chang et al., 2012</xref>). In mouse models of AD, downregulation (<xref ref-type="bibr" rid="bib29">Ha et al., 2010</xref>) and deficiency of S100A9 (<xref ref-type="bibr" rid="bib42">Kummer et al., 2012</xref>) had therapeutic effects on disease activity. Also in human studies, S100A9 was found to be associated with AD pathogenesis (<xref ref-type="bibr" rid="bib69">Shepherd et al., 2006</xref>). Beyond that, S100A8 and S100A9 are known key players in the pathogenesis of arthritis in murine models (<xref ref-type="bibr" rid="bib74">van Lent et al., 2012</xref>). Gene expression profiling of blood cells from RA patients receiving anti-TNF-α-based treatment showed that both <italic>CEBPD</italic> and <italic>S100A8</italic> were downregulated by the treatment (<xref ref-type="bibr" rid="bib61">Meugnier et al., 2011</xref>). Uncontrolled activity of S100A8/A9 alarmins drives TNF-induced arthritis in mice (<xref ref-type="bibr" rid="bib77">Vogl et al., 2018</xref>). In the context of human RA, the expression and serum concentrations of S100A8/A9 correlate very well with disease activity and are the first predictive marker for disease relapses in juvenile patients, and of the responses to therapy in juvenile and adult patients (<xref ref-type="bibr" rid="bib62">Moncrieffe et al., 2013</xref>; <xref ref-type="bibr" rid="bib11">Choi et al., 2015</xref>). However, no direct molecular or functional link between S100A8/A9 and C/EBPδ in arthritis has yet been reported. Using an in vivo model for acute lung inflammation, we were now able to show that C/EBPδ-deficient mice express lower S100A8/A9 level than WT littermates in response to LPS exposure, which is accompanied by a milder disease phenotype. In S100A9 KO mice, neutrophil recruitment in the lung was impeded when using the same mouse model (<xref ref-type="bibr" rid="bib8">Chakraborty et al., 2017</xref>), suggesting that S100A8/A9 expression mediates effects of C/EBPδ as a key mediator of LPS-induced lung inflammation (<xref ref-type="bibr" rid="bib87">Yan et al., 2013</xref>). Our data define a new regulatory axis between the transcription factor C/EBPδ and the alarmins S100A8 and S100A9 in myeloid cells which is of relevance in different inflammatory processes and clinical diseases.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Murine model of acute lung inflammation</title><p>WT and C/EBPδ KO (kindly provided by Esta Sterneck, National Cancer Institute, Frederick, MD) (<xref ref-type="bibr" rid="bib71">Sterneck et al., 1998</xref>) mice were exposed to LPS from <italic>Salmonella enterica</italic> (0.5 mg/ml, Sigma-Aldrich) in saline or saline (NaCl) only for 45 min inside a cylindrical Pyrex chamber which was connected to a nebulizer. After a 4 hr resting period, mice were anesthetized, blood was collected from heart and BALF was collected for S100A8/A9 measurements by flushing the lungs five times with 0.8 ml NaCl through the trachea. Serum and BALF were saved for later analyses of alarmins and cytokines at –80°C. Migrated polymorphonuclear leukocytes were analysed via Kimura and following Ly-6B.2/Gr-1-antibody (Bio-Rad) staining. Mouse experiments were in accordance with German Animal Welfare Legislation and performed as approved by the North Rhine-Westphalia Office of Nature, Environment and Consumer Protection (LANUV), and the District Government and District Veterinary Office Muenster under the reference number 81-02.04.2019.A445.</p></sec><sec id="s4-2"><title>Cell culture</title><p>ER-Hoxb8 cells were generated as described earlier (<xref ref-type="bibr" rid="bib79">Wang et al., 2006a</xref>) and grown in RPMI medium (Thermo Fisher Scientific) supplemented with 10% FBS (Biowest), 1% penicillin/streptomycin solution (Sigma-Aldrich), 1% glutamine solution (Thermo Fisher Scientific), 40 ng/ml recombinant mouse GM-CSF (ImmunoTools) an 1 µM β-estradiol (Sigma-Aldrich). For differentiation, precursor cells were washed and incubated in estradiol-free medium containing 40 ng/ml GM-CSF for several days. HEK293T were grown in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS (Biowest) and 1% penicillin/streptomycin solution (Sigma-Aldrich), 1% glutamine solution (Thermo Fisher Scientific), and 1% sodium pyruvate (Merck). All cell lines were cultured at 37°C, 5% CO<sub>2</sub>, and routinely screened and found negative for mycoplasma contamination in a PCR-based assay (PromoCell).</p></sec><sec id="s4-3"><title>Cell line generation and manipulation</title><p>WT, C/EBPδ KO (kindly provided by Esta Sterneck, National Cancer Institute, Frederick, MD) (<xref ref-type="bibr" rid="bib71">Sterneck et al., 1998</xref>) and Cas9-expressing (<xref ref-type="bibr" rid="bib10">Chiou et al., 2015</xref>) ER-Hoxb8 cells originated from corresponding mice. PHF8, CSRP1, HAND1, FBXW7, ATF3, STAT3, KLF5, IRF7, and C/EBPβ KO ER-Hoxb8 cells were generated using CRISPR/Cas9 as described earlier (<xref ref-type="bibr" rid="bib28">Gran et al., 2018</xref>). The oligos for gRNA cloning are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>. For lentiviral production, the lentiGuide-Puro (for GeCKO screen), lentiCRISPRv2-gRNA (for single KO cell lines), or TRE_3xFlag-C/EBPδ was co-transfected into HEK293T cells, together with the packaging plasmids pCMV-VSV-G (AddGene, #8454) and psPAX2 (AddGene, #12260). For transduction of ER-Hoxb8 cells, cells were incubated with lentiviral particles and 8 µg/ml polybrene (Sigma-Aldrich) for 1 hr upon spinfection and selected for several days using puromycin (InvivoGen). For transfection of HEK293T cells, the cells were seeded 1 day prior to transfection. Then, cells were co-transfected with TRE_3xFlag-C/EBPδ and <italic>S100a8</italic> reporter or <italic>S100a9</italic> reporter using the Lipofectamine 3000 Transfection Reagent (Thermo Scientific) according to the manufacturer’s manual. For inhibition of JMJD3 activities, cells were treated using 5 µM GSK-J4 HCl (SellekChem) for 3 days. To induce <italic>cebpd</italic> in TRE_3xFlag-C/EBPδ ER-Hoxb8 cells or transfected HEK293T cells, cells were treated using 2 µg/ml doxycycline (Sigma-Aldrich) for 24 hr.</p></sec><sec id="s4-4"><title>Isolation of BMDMs</title><p>BMDMs were obtained by flushing the femurs from WT and C/EBPδ KO mice. Erythrocytes were depleted by osmotic shock. Cells were washed and separated using a Ficoll gradient (PAN-Biotech). Primary monocytes (M<sub>0</sub>) were generated by culturing for 3 days in DMEM containing with 10% FBS (Biowest) and 1% penicillin/streptomycin solution (Sigma-Aldrich), 1% glutamine solution (Thermo Fisher Scientific), and 15% of L929 supernatant as a source of macrophage colony-stimulating factor. Stimulation of cells with 50 ng/ml IFN-γ (ImmunoTools) and 10 ng/ml LPS (Sigma-Aldrich) for 24 hr was used for M<sub>1</sub>-polarization, whereas a 24 hr stimulation with 20 ng/ml IL-4 (Peprotech) led to M<sub>2</sub>-polarization of BMDMs.</p></sec><sec id="s4-5"><title>GeCKO-library screening</title><p>Amplification of mouse CRISPR Knockout pooled library (GeCKO v2) in lentiGuide-Puro plasmid, purchased from AddGene (#1000000053) (<xref ref-type="bibr" rid="bib67">Sanjana et al., 2014</xref>), was performed as described (<xref ref-type="bibr" rid="bib34">Joung et al., 2017</xref>). Cas9-expressing ER-Hoxb8 cells, transduced with library lentiviral particles at an MOI of 0.4, were differentiated to day 3. Intracellular S100A9 was stained with an S100A9-FITC coupled antibody using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Cells with no/lower S100A9 expression (hits) and cells with normal S100A9 expression (reference) were sorted using an SH800S Cell Sorter (Sony, Minato, Japan) and DNA was purified by phenol-chloroform extraction. Next-generation sequencing was performed as described earlier (<xref ref-type="bibr" rid="bib34">Joung et al., 2017</xref>). Briefly, sgRNA library for next-generation sequencing was prepared via PCR using primers amplifying the target region with Illumina adapter sequences (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>), the purified DNA, and the NEBNext High-Fidelity 2× PCR Master Mix (NEB). PCRs were pooled and purified using the QIAquick PCR Purification Kit (Qiagen). Size and quantity was determined using the Bioanalyzer High Sensitivity DNA Analysis Agilent High Sensitivity DNA Kit (Agilent). Samples were sequenced according to the Illumina user manual with 80 cycles of read 1 (forward) using the NextSeq 500/550 High Output Kit v2.5 (75 Cycles) (Illumina) with the 20% PhiX spike in Illumina PhiX control kit (Illumina).</p></sec><sec id="s4-6"><title>Cloning and plasmid production</title><sec id="s4-6-1"><title>TRE_3xFlag-C/EBPδ and TRE_ctrl</title><p>The pcDNA 3.1 (-) mouse C/EBPδ expression vector (AddGene, #12559) and annealed oligonucleotides (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>) were digested using <italic>Xba</italic>I and <italic>EcoR</italic>I and then ligated. Using primers carrying restriction enzyme recognition sites (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>), the 3xFlag-C/EBPδ expression cassette was amplified. The resulting amplicon and the pCW57.1 mDux-CA target vector (AddGene, #99284) (<xref ref-type="bibr" rid="bib82">Whiddon et al., 2017</xref>) were digested using <italic>Nhe</italic>I and <italic>Age</italic>I and subsequently ligated. TRE_ctrl was produced by digesting TRE_3xFlag-C/EBPδ using <italic>Nhe</italic>I and <italic>Age</italic>I and by subsequent blunting of ends by 3' overhang removal and fill-in of 3' recessed (5' overhang) ends using DNA Polymerase I, Large (Klenow) Fragment (NEB) prior to ligation.</p></sec><sec id="s4-6-2"><title><italic>S100a8</italic> and <italic>S100a9</italic> reporter</title><p>To construct <italic>S100</italic> reporter vectors, 1500 bp upstream of <italic>S100a8</italic> and 1800 bp upstream of <italic>S100a9</italic> TSS were amplified from genomic mouse DNA. Using primers carrying restriction enzyme recognition sites (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>), promoter regions were amplified and cloned into pLenti CMV GFP Blast vector (AddGene, #17445) (<xref ref-type="bibr" rid="bib7">Campeau et al., 2009</xref>) using <italic>Xba</italic>I and <italic>Cla</italic>I. Resulting <italic>S100</italic> prom-GFP constructs were cloned into MSCV-PIG-empty vector (AddGene, #105594) (<xref ref-type="bibr" rid="bib85">Xu et al., 2018</xref>) by digestion with <italic>Nsi</italic>I and <italic>Cla</italic>I together with the MSCV backbone to exchange IRES-GFP-cassette with <italic>S100a8/a9</italic>prom-GFP-cassette and subsequent ligation. Proposed C/EBP DNA-binding sites within <italic>S100a8</italic> and <italic>S100a9</italic> promoter regions were identified using the AliBaba2.1 net-based transcription factor-binding site search tool (<xref ref-type="bibr" rid="bib27">Grabe, 2002</xref>), and were mutated by deleting 6–7 base pairs using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies). The primers used for mutagenesis are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>. Plasmids were produced in DH5α cells and purified using the PureLinkTM HiPure Plasmid Midiprep Kit (Thermo Scientific).</p></sec></sec><sec id="s4-7"><title>qRT-PCR</title><p>RNA was isolated using a NucleoSpin Extract II Isolation Kit (Macherey Nagel). The mRNA expression of selected genes was measured by qRT-PCR as described earlier (<xref ref-type="bibr" rid="bib30">Heming et al., 2018</xref>). The primers used are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f</xref>. The relative expression level of each target gene was analysed using the 2−ΔΔCq method and was normalized to GAPDH.</p></sec><sec id="s4-8"><title>Chromatin immunoprecipitation</title><p>For chromatin preparation, progenitor and differentiated ER-Hoxb8 cells were fixed using 1% formaldehyde for 5 min and reaction was stopped by adding 125 mM glycine. Chromatin was extracted as previously described (<xref ref-type="bibr" rid="bib25">Fujita and Fujii, 2013</xref>). Approximately 1–5% of chromatin served as the input sample. DNA from input samples was isolated using phenol-chloroform extraction as described earlier (<xref ref-type="bibr" rid="bib30">Heming et al., 2018</xref>). For immunoprecipitation, 3 µg antibody against Flag (Sigma-Aldrich), H3K27ac (Abcam), H3K27me<sub>3</sub> (Cell Signaling Technology), normal Rabbit IgG (Cell Signaling,) or Mouse IgG1, κ Isotype control (BioLegend) was conjugated to 900 µg magnetic Dynabeads-Protein G (Thermo Scientific) at 4°C overnight. Sonicated chromatin was added to AB-conjugated Dynabeads and incubated at 4°C overnight. The Dynabeads were washed as described earlier (<xref ref-type="bibr" rid="bib25">Fujita and Fujii, 2013</xref>). For elution, Dynabeads were incubated twice with elution buffer (0.05 M NaHCO<sub>3</sub>, 1% SDS) at 65°C for 15 min. DNA from eluates was isolated using phenol-chloroform extraction as with input samples. Values were taken into account only when the amount of DNA pulled down by using the antibody of interest was more than 5-fold increased over DNA pulled down by using IgG antibodies. The primers used for ChIP-PCR are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1g</xref>.</p></sec><sec id="s4-9"><title>ATAC-seq</title><p>Precursor and day 3 differentiated WT and C/EBPδ KO ER-Hoxb8 cells were harvested, washed, and cryopreserved in 50% FBS/40% growth media/10% DMSO using a freezing container at –80°C overnight. Cells were shipped to Active Motif to perform ATAC-seq as previously described (<xref ref-type="bibr" rid="bib6">Buenrostro et al., 2013</xref>).</p></sec><sec id="s4-10"><title>Measurements of S100A8/A9 protein level</title><p>The S100A8/A9 protein concentrations were measured using an in-house S100A8/A9 enzyme-linked immunosorbent assay (ELISA), as previously described (<xref ref-type="bibr" rid="bib76">Vogl et al., 2014</xref>).</p></sec><sec id="s4-11"><title>Cytokine measurements by bead-based immunoassay</title><p>IL-1α, IFN-γ, GM-CSF, MCP-1, IL-12<sub>p70</sub>, IL-1β, IL-10, IL-6, IL-27, IL-17A, IFN-β, and TNF-α were analysed using the bead-based immunoassay LEGENDplex mouse inflammation panel according to manufacturer’s instructions (BioLegend). Analytes were measured by flow cytometry using Navios (Beckmann Coulter).</p></sec><sec id="s4-12"><title>Immunoblotting</title><p>Cells were lysed in M-PER Mammalian Protein Extraction Reagent (Thermo Scientific) containing a protease inhibitor mixture (Sigma-Aldrich). Protein concentration was determined, and equal amounts (15–30 µg) were run on an SDS-PAGE. After blotting on a nitrocellulose membrane, the membrane was incubated overnight with primary antibodies against: polyclonal rabbit S100A8 and S100A9 antibodies (originated from our own production; <xref ref-type="bibr" rid="bib76">Vogl et al., 2014</xref>), GAPDH (Cell Signaling Technology), α/β-Tubulin (Cell Signaling Technology), and Flag (Sigma-Aldrich). Membranes were incubated with an HRP-linked secondary antibody (Agilent) for 1 hr. Chemiluminescence signal was detected using ChemiDoc XRS+ (Bio-Rad) together with ImageJ (National Institutes of Health) to quantify the signal intensity.</p></sec><sec id="s4-13"><title>Phagocytosis</title><p>FluoSpheres polystrene microspheres (Thermo Scientific) that were shortly sonicated in a bath sonicator (Latex Beads) or pHrodo Red <italic>S. aureus</italic> Bioparticles Conjugate (<italic>S. aureus</italic> Bioparticles) were added to 5 × 10<sup>5</sup> differentiated cells at a ratio 1:10 for 2 hr at 37°C. The rate of phagocytosis was measured by flow cytometry using Navios (Beckmann Coulter).</p></sec><sec id="s4-14"><title>Oxidative burst</title><p>Cells were stimulated using 10 nM PMA (Abcam) for 15 min or left untreated. After incubation, 15 μM DHR123 (Sigma-Aldrich) were added for another 15 min. The fluorescence signal was analysed using flow cytometry (Navios, Beckmann Coulter).</p></sec><sec id="s4-15"><title>FACS analysis</title><p>BMCs and ER-Hoxb8 cells were differentiated using 40 ng/ml rmGM-CSF (ImmunoTools), harvested, stained for CD11b, Ly-6C, and appropriate Isotype control antibodies (all BioLegend) and measured using flow cytometry (Navios, Beckmann Coulter) to determine cell population purity and differentiation kinetics.</p></sec><sec id="s4-16"><title>RNA-seq</title><sec id="s4-16-1"><title>Study population</title><p>For this study, we used bulk mRNA-sequencing (RNA-seq) data of PBMCs and monocytes from two subsets of participants in the German BioNRW Study (<xref ref-type="bibr" rid="bib83">Witten et al., 2022</xref>). BioNRW actively recruits patients undergoing coronary angiography for the diagnosis and percutaneous coronary intervention of coronary artery disease, as well as age and gender matched healthy control individuals without history of cardiovascular disease, all aged 18–70 years of age. Patients receive standard cardiovascular care and medication (ACE-inhibitor, AT1-receptor blocker, β-blocker, diuretics, statin), according to current guidelines. Here, we included a total of 42 patients with sCAD or acute MI, as well as 39 of the corresponding age and sex matched controls.</p><p>The BioNRW Study is conducted in accordance with the guidelines of the Declaration of Helsinki. The research protocol, including the case report forms, was approved by the local ethics committee (#245-12). Written informed consent was obtained from all study participants.</p></sec><sec id="s4-16-2"><title>Blood collection and isolation of PBMCs</title><p>In case of MI, blood samples were collected during the first 4 days following the event. EDTA blood was drawn from each subject by venipuncture. Sample processing followed within 2 hr. PBMCs were obtained from 40 ml blood by density gradient centrifugation (Ficoll; Biochrom). Lymphocytes were collected and washed twice with PBS. The pellet was re-suspended in freezing medium Cryo-SFM (PromoCell) and cryopreserved.</p></sec><sec id="s4-16-3"><title>Isolation of monocyte subpopulations</title><p>After washing, PBMCs were stained with anti-human antibodies specific for CD2 (PE, RPA-2.10, T-cell marker), CD14 (APC, M5E2, monocyte subset differentiation), CD15 (PE, HIM1, granulocyte marker), CD16 (PE-Cy7, 3G8, monocyte subset differentiation), CD19 (PE, HIB19, B-cell marker), CD56 (PE, MY31, NK-cell marker), CD335 (PE, 9E2, NK-cell marker), HLA-DR (FITC, TU36, antigen-presenting cells) (all from BD Biosciences), as reported by <xref ref-type="bibr" rid="bib12">Cros et al., 2010</xref>. Cells were acquired on a FACS LSR II flow cytometer (BD Biosciences) and analysed using FlowJo software version 10 (Treestar Inc). For sorting of monocyte subsets, PBMCs were stained and sorted on a MoFlo Astrios cell sorter (Beckman Coulter). Cells were sorted in 1 ml of Isol-RNA lysis reagent (5-Prime GmbH) and frozen at –80°C. To avoid gender-specific effects, three representative male samples of each BioNRW diagnostic group (sCAD, MI, and control) were selected to be subjected to cell sorting and subsequent RNA isolation.</p></sec><sec id="s4-16-4"><title>Differential expression analysis in PBMCs and monocytes</title><p>For mRNA profiling of PBMCs and monocyte subpopulations using RNA-seq, mRNA was enriched using the NEBNext Poly(A) Magnetic Isolation Module (NEB), followed by cDNA NGS library preparation (NEBNext Ultra RNA Library Prep Kit for Illumina, NEB). The size of the resulting libraries was controlled by the use of a Bioanalyzer High Sensitivity DNA Kit (Agilent Technologies) and quantified using the KAPA Library Quantification Kit for Illumina (Roche). Equimolar, appropriately pooled libraries were sequenced in a single read mode (75 cycles) on a NextSeq500 System (Illumina) using v2 chemistry, yielding in an average QScore distribution of 92%≥Q30 score. They were subsequently demultiplexed and converted to FASTQ files using bcl2fastq v2.20 Conversion software (Illumina). Data was quality controlled using FASTQC software and trimmed for adapter sequences using Trimmomatic (<xref ref-type="bibr" rid="bib5">Bolger et al., 2014</xref>).</p></sec></sec><sec id="s4-17"><title>General statistics</title><p>The statistical significance of the data was determined using Prism 5.0 software (GraphPad Software, San Diego, CA). Analyses between two groups were performed using an unpaired two-tailed Student’s t test. Comparisons among three or more groups were performed by using one-way ANOVA, followed by Bonferroni’s multiple means tests for comparing all pairs of columns. Differences were considered statistically significant at a probability (p-value) of &lt;0.05.</p></sec><sec id="s4-18"><title>Bioinformatics analysis</title><sec id="s4-18-1"><title>GeCKO-library screening</title><p>Analysis of counting the reads for each gRNA and differential analysis was performed using MaGeCK 0.5.9.3, a computational tool to identify important genes from GeCKO-based screens (<xref ref-type="bibr" rid="bib52">Li et al., 2014</xref>). A modified RRA method with a redefined ρ value was used. Former RRA computed a significant p-value for genes in the middle of gRNA ranked list and thereby introducing false positives because the assumption of uniformity is not necessarily satisfied in real applications. Thus, top ranked % gRNAs were selected if their negative binomial p-values were smaller than a threshold, such as 0.05. If j of the n gRNAs targeting a gene were selected, then the modified value is defined as ρ=min (p1, p2,…,pj), where j≤n. This modified RRA method could efficiently remove the effect of insignificant gRNAs in the assessment of gene significance. A permutation test where the gRNAs were randomly assigned to genes was performed to compute a p-value based on the ρ values. By default, 100× ng permutations are performed, where ng is the number of genes. We then compute the FDR from the empirical permutation p-values using the Benjamini-Hochberg procedure.</p></sec><sec id="s4-18-2"><title>ATAC-seq</title><p>Sequence analysis was performed by mapping the paired-end 42 bp sequencing reads (PE42) generated by Illumina sequencing (using NextSeq500) to the genome using the BWA algorithm with default settings (‘bwa mem’). Only reads that passed Illumina’s purity filter, aligned with no more than two mismatches, and mapped uniquely to the genome were used in the subsequent analysis. In addition, duplicate reads (‘PCR duplicates’) were removed. BAM files provided by Active Motif were used to perform peak calling with MACS2, using paired-end mode with a bandwidth of 200 and q-value cutoff of 0.01. BedGraph files were converted to BigWig format for visualization with the Integrative Genomics Viewer (IGV) (<xref ref-type="bibr" rid="bib72">Thorvaldsdóttir et al., 2013</xref>) using bedGraphToBigWig. Differential accessibility analyses for all possible comparisons between WT and/or C/EBPδ KO in day 0 and day 3 groups were carried out with GUAVA v1 (<xref ref-type="bibr" rid="bib16">Divate and Cheung, 2018</xref>), which implements DESeq2 (<xref ref-type="bibr" rid="bib59">Love et al., 2014</xref>). Differential peaks were defined as those merged intervals within a window of 5000 bp upstream and 3000 bp downstream of the transcription start site (TSS) showing an adjusted p-value (padj) &lt;0.05 and log2 fold change ≥±1.5.</p></sec><sec id="s4-18-3"><title>RNA-seq</title><p>The resulting reads were mapped to the human reference genome builds hg19 (monocytes) or hg38 (PBMCs) using Tophat2 (<xref ref-type="bibr" rid="bib38">Kim et al., 2013</xref>) or HISAT2 v2.1.0 (<xref ref-type="bibr" rid="bib39">Kim et al., 2019</xref>), counted by using the R package GenomicAlignments (<xref ref-type="bibr" rid="bib48">Lawrence et al., 2013</xref>) or HTSeq v0.11.2 (<xref ref-type="bibr" rid="bib1">Anders et al., 2015</xref>), and followed by differential expression analysis using DEseq2 (<xref ref-type="bibr" rid="bib59">Love et al., 2014</xref>). The PBMCs dataset used for analysis consisted of 72 individuals, from which 36 were sCAD/MI cases and 36 were controls (21 females and 15 males in each group, mean age: 50.8±12.3 years), while the monocytes dataset contained read counts of classical, intermediate, and non-classical monocyte subpopulations from 9 male individuals (3 MI, 3 sCAD, and 3 controls). One sCAD non-classical monocyte sample had to be excluded from analysis due to low mapping rate; therefore, the monocytes dataset used for analysis contained 26 samples. Genes were considered differentially expressed at adjusted p&lt;0.05 (Benjamini-Hochberg method). R was used to perform Pearson correlation tests and generate plots for the genes of interest from the normalized count data.</p></sec></sec><sec id="s4-19"><title>Conclusion</title><p>We found that the transcription factor C/EBPδ drives expression of the abundant alarmins S100A8 and S100A9, and demonstrated that C/EBPδ binding to specific sites on <italic>S100a8</italic> and <italic>S100a9</italic> promoter regions also induced changes in chromatin accessibility via JMJD3-mediated demethylation of H3K27me<sub>3</sub> marks, which includes a so far unknown link. Due to the high relevance of S100A8/A9 alarmin expression in many inflammatory diseases, our findings may point to novel molecular targets for innovative anti-inflammatory therapeutic approaches.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Software, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Software</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Methodology</p></fn><fn fn-type="con" id="con8"><p>Supervision</p></fn><fn fn-type="con" id="con9"><p>Resources</p></fn><fn fn-type="con" id="con10"><p>Resources</p></fn><fn fn-type="con" id="con11"><p>Funding acquisition</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources</p></fn><fn fn-type="con" id="con13"><p>Funding acquisition, Project administration, Resources, Supervision</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Funding acquisition, Project administration, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Investigation, Project administration, Supervision, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The BioNRW Study is conducted in accordance with the guidelines of the Declaration of Helsinki. The research protocol, including the case report forms, was approved by the local ethics committee (#245-12). Written informed consent was obtained from all study participants.</p></fn><fn fn-type="other"><p>Mouse experiments were in accordance with German Animal Welfare Legislation and performed as approved by the North Rhine-Westphalia Office of Nature, Environment and Consumer Protection (LANUV) and the District Government and District Veterinary Office Muenster under the reference number 81-02.04.2019.A445.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of oligonucleotides used for cloning, (qRT)PCR and mutagenesis.</title><p>(a) List of guides (stated in 5’–3’ orientation) for cloning into lentiCRISPR v2, related to Materials and methods. (b) List of primer (stated in 5’–3’ orientation) for amplifying GeCKO library and NGS, related to Materials and methods. (c) List of oligonucleotides (stated in 5’–3’ orientation, fw: forward, rv: reverse) for cloning steps to construct TRE_3xFlag-C/EBPδ vector, related to Materials and methods. (d) List of oligonucleotides (stated in 5’–3’ orientation, fw: forward, rv: reverse) for cloning steps to construct <italic>S100a8</italic> and <italic>S100a9</italic> reporter construct, related to Materials and methods. (e) List of oligonucleotides (stated in 5’–3’ orientation) for mutagenesis to disrupt specific sites within <italic>S100a8</italic> and <italic>S100a9</italic> reporter vectors, related to Materials and methods. (f) List of quantitative reverse transcription polymerase chain reaction (qRT-PCR) primer (in 5’–3’ orientation) used for qRT-PCR, related to Materials and methods. (g) List of chromatin immunoprecipitation (ChIP)-PCR primer (in 5’–3’ orientation) for <italic>S100a8</italic> and <italic>S100a9</italic> genomic locations, related to Materials and methods.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-75594-supp1-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-75594-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>GeCKO-screen data are deposited in ID PRJNA754262 at the NCBI’s Database, RNA-seq data are deposited in ID 706411 at the NCBI SRA repository and ATAC-seq data are deposited in ID GSE200730 at the NCBI’s GEO data repository.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Jauch-Speer</surname><given-names>SL</given-names></name><name><surname>Herrera-Rivero</surname><given-names>M</given-names></name><name><surname>Ludwig</surname><given-names>N</given-names></name><name><surname>Véras De Carvalho</surname><given-names>BC</given-names></name><name><surname>Martens</surname><given-names>L</given-names></name><name><surname>Wolf</surname><given-names>J</given-names></name><name><surname>Imam Chasan</surname><given-names>A</given-names></name><name><surname>Witten</surname><given-names>A</given-names></name><name><surname>Markus</surname><given-names>B</given-names></name><name><surname>Schieffer</surname><given-names>B</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Roissant</surname><given-names>J</given-names></name><name><surname>Stoll</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Fehler</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>GeCKO screen</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA754262">PRJNA754262</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Witten</surname><given-names>A</given-names></name><name><surname>Martens</surname><given-names>L</given-names></name><name><surname>Schäfer</surname><given-names>A-C</given-names></name><name><surname>Troidl</surname><given-names>C</given-names></name><name><surname>Pankuweit</surname><given-names>S</given-names></name><name><surname>Vlacil</surname><given-names>A-K</given-names></name><name><surname>Oberoi</surname><given-names>R</given-names></name><name><surname>Schieffer</surname><given-names>B</given-names></name><name><surname>Grote</surname><given-names>K</given-names></name><name><surname>Stoll</surname><given-names>M</given-names></name><name><surname>Markus</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>monocyte subpopulation profiling</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA706411">PRJNA706411</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Jauch-Speer</surname><given-names>SL</given-names></name><name><surname>Herrera-Rivero</surname><given-names>M</given-names></name><name><surname>Ludwig</surname><given-names>N</given-names></name><name><surname>Véras De Carvalho</surname><given-names>BC</given-names></name><name><surname>Martens</surname><given-names>L</given-names></name><name><surname>Wolf</surname><given-names>J</given-names></name><name><surname>Imam Chasan</surname><given-names>A</given-names></name><name><surname>Witten</surname><given-names>A</given-names></name><name><surname>Markus</surname><given-names>B</given-names></name><name><surname>Schieffer</surname><given-names>B</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Rossaint</surname><given-names>J</given-names></name><name><surname>Stoll</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Fehler</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>ATAC-seq in precursor and differentiated ER-Hoxb8 cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE200730">GSE200730</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank Ursula Nordhues, Eva Nattkemper, Heike Hater, Heike Berheide, Sina Mersmann, Elvira Barg, and Marianne Jansen-Rust for their excellent technical support, and Esta Sterneck (Center for Cancer Research, National Cancer Institute, Frederick, MD) for providing the C/EBPδ KO mice. This work was supported by grants from the Interdisciplinary Center of Clinical Research at the University of Münster (Ro2/023/19, Vo2/011/19), the German Research Foundation CRC 1009 B8, B9, and Z2, CRU 342 P3 and P5 and RO 1190/14–1 (to J Roth and T Vogl) and by the EU EFRE Bio NRW programme (005-1007-0006) to MS. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Pyl</surname><given-names>PT</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HTSeq--a Python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics (Oxford, England)</source><volume>31</volume><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id><pub-id pub-id-type="pmid">25260700</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austermann</surname><given-names>J</given-names></name><name><surname>Spiekermann</surname><given-names>C</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>S100 proteins in rheumatic diseases</article-title><source>Nature Reviews. Rheumatology</source><volume>14</volume><fpage>528</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1038/s41584-018-0058-9</pub-id><pub-id pub-id-type="pmid">30076385</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydin</surname><given-names>S</given-names></name><name><surname>Ugur</surname><given-names>K</given-names></name><name><surname>Aydin</surname><given-names>S</given-names></name><name><surname>Sahin</surname><given-names>İ</given-names></name><name><surname>Yardim</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Biomarkers in acute myocardial infarction: current perspectives</article-title><source>Vascular Health and Risk Management</source><volume>15</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.2147/VHRM.S166157</pub-id><pub-id pub-id-type="pmid">30697054</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balamurugan</surname><given-names>K</given-names></name><name><surname>Sharan</surname><given-names>S</given-names></name><name><surname>Klarmann</surname><given-names>KD</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Coppola</surname><given-names>V</given-names></name><name><surname>Summers</surname><given-names>GH</given-names></name><name><surname>Roger</surname><given-names>T</given-names></name><name><surname>Morrison</surname><given-names>DK</given-names></name><name><surname>Keller</surname><given-names>JR</given-names></name><name><surname>Sterneck</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>FBXW7α attenuates inflammatory signalling by downregulating C/EBPδ and its target gene Tlr4</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>1662</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms2677</pub-id><pub-id pub-id-type="pmid">23575666</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AM</given-names></name><name><surname>Lohse</surname><given-names>M</given-names></name><name><surname>Usadel</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Trimmomatic: a flexible trimmer for Illumina sequence data</article-title><source>Bioinformatics (Oxford, England)</source><volume>30</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buenrostro</surname><given-names>JD</given-names></name><name><surname>Giresi</surname><given-names>PG</given-names></name><name><surname>Zaba</surname><given-names>LC</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Greenleaf</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position</article-title><source>Nature Methods</source><volume>10</volume><fpage>1213</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2688</pub-id><pub-id pub-id-type="pmid">24097267</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campeau</surname><given-names>E</given-names></name><name><surname>Ruhl</surname><given-names>VE</given-names></name><name><surname>Rodier</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>CL</given-names></name><name><surname>Rahmberg</surname><given-names>BL</given-names></name><name><surname>Fuss</surname><given-names>JO</given-names></name><name><surname>Campisi</surname><given-names>J</given-names></name><name><surname>Yaswen</surname><given-names>P</given-names></name><name><surname>Cooper</surname><given-names>PK</given-names></name><name><surname>Kaufman</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A versatile viral system for expression and depletion of proteins in mammalian cells</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e6529</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006529</pub-id><pub-id pub-id-type="pmid">19657394</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>D</given-names></name><name><surname>Zenker</surname><given-names>S</given-names></name><name><surname>Rossaint</surname><given-names>J</given-names></name><name><surname>Hölscher</surname><given-names>A</given-names></name><name><surname>Pohlen</surname><given-names>M</given-names></name><name><surname>Zarbock</surname><given-names>A</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Alarmin S100A8 Activates Alveolar Epithelial Cells in the Context of Acute Lung Injury in a TLR4-Dependent Manner</article-title><source>Frontiers in Immunology</source><volume>8</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01493</pub-id><pub-id pub-id-type="pmid">29180999</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>L-H</given-names></name><name><surname>Huang</surname><given-names>H-S</given-names></name><name><surname>Wu</surname><given-names>P-T</given-names></name><name><surname>Jou</surname><given-names>I-M</given-names></name><name><surname>Pan</surname><given-names>M-H</given-names></name><name><surname>Chang</surname><given-names>W-C</given-names></name><name><surname>Wang</surname><given-names>DDH</given-names></name><name><surname>Wang</surname><given-names>J-M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Role of macrophage CCAAT/enhancer binding protein delta in the pathogenesis of rheumatoid arthritis in collagen-induced arthritic mice</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e45378</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0045378</pub-id><pub-id pub-id-type="pmid">23028973</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiou</surname><given-names>S-H</given-names></name><name><surname>Winters</surname><given-names>IP</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Naranjo</surname><given-names>S</given-names></name><name><surname>Dudgeon</surname><given-names>C</given-names></name><name><surname>Tamburini</surname><given-names>FB</given-names></name><name><surname>Brady</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Grüner</surname><given-names>BM</given-names></name><name><surname>Chuang</surname><given-names>C-H</given-names></name><name><surname>Caswell</surname><given-names>DR</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Chu</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>GE</given-names></name><name><surname>Carpizo</surname><given-names>DR</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Winslow</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing</article-title><source>Genes &amp; Development</source><volume>29</volume><fpage>1576</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1101/gad.264861.115</pub-id><pub-id pub-id-type="pmid">26178787</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>IY</given-names></name><name><surname>Gerlag</surname><given-names>DM</given-names></name><name><surname>Herenius</surname><given-names>MJ</given-names></name><name><surname>Thurlings</surname><given-names>RM</given-names></name><name><surname>Wijbrandts</surname><given-names>CA</given-names></name><name><surname>Foell</surname><given-names>D</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Holzinger</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis</article-title><source>Annals of the Rheumatic Diseases</source><volume>74</volume><fpage>499</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203923</pub-id><pub-id pub-id-type="pmid">24297376</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cros</surname><given-names>J</given-names></name><name><surname>Cagnard</surname><given-names>N</given-names></name><name><surname>Woollard</surname><given-names>K</given-names></name><name><surname>Patey</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>S-Y</given-names></name><name><surname>Senechal</surname><given-names>B</given-names></name><name><surname>Puel</surname><given-names>A</given-names></name><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Moshous</surname><given-names>D</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Jais</surname><given-names>J-P</given-names></name><name><surname>D’Cruz</surname><given-names>D</given-names></name><name><surname>Casanova</surname><given-names>J-L</given-names></name><name><surname>Trouillet</surname><given-names>C</given-names></name><name><surname>Geissmann</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors</article-title><source>Immunity</source><volume>33</volume><fpage>375</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.08.012</pub-id><pub-id pub-id-type="pmid">20832340</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>SS</given-names></name><name><surname>Hamdy</surname><given-names>FC</given-names></name><name><surname>Deloulme</surname><given-names>JC</given-names></name><name><surname>Rehman</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers</article-title><source>Histopathology</source><volume>46</volume><fpage>256</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2559.2005.02097.x</pub-id><pub-id pub-id-type="pmid">15720411</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>ND</given-names></name><name><surname>Jung</surname><given-names>KH</given-names></name><name><surname>Choi</surname><given-names>MR</given-names></name><name><surname>Yoon</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Chai</surname><given-names>YG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Gene networking and inflammatory pathway analysis in a JMJD3 knockdown human monocytic cell line</article-title><source>Cell Biochemistry and Function</source><volume>30</volume><fpage>224</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1002/cbf.1839</pub-id><pub-id pub-id-type="pmid">22252741</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>FM</given-names></name><name><surname>denDekker</surname><given-names>A</given-names></name><name><surname>Joshi</surname><given-names>AD</given-names></name><name><surname>Wolf</surname><given-names>SJ</given-names></name><name><surname>Audu</surname><given-names>C</given-names></name><name><surname>Melvin</surname><given-names>WJ</given-names></name><name><surname>Mangum</surname><given-names>K</given-names></name><name><surname>Riordan</surname><given-names>MO</given-names></name><name><surname>Kunkel</surname><given-names>SL</given-names></name><name><surname>Gallagher</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Palmitate-TLR4 signaling regulates the histone demethylase, JMJD3, in macrophages and impairs diabetic wound healing</article-title><source>European Journal of Immunology</source><volume>50</volume><fpage>1929</fpage><lpage>1940</lpage><pub-id pub-id-type="doi">10.1002/eji.202048651</pub-id><pub-id pub-id-type="pmid">32662520</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Divate</surname><given-names>M</given-names></name><name><surname>Cheung</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>GUAVA: A Graphical User Interface for the Analysis and Visualization of ATAC-seq Data</article-title><source>Frontiers in Genetics</source><volume>9</volume><elocation-id>250</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2018.00250</pub-id><pub-id pub-id-type="pmid">30065749</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doñas</surname><given-names>C</given-names></name><name><surname>Carrasco</surname><given-names>M</given-names></name><name><surname>Fritz</surname><given-names>M</given-names></name><name><surname>Prado</surname><given-names>C</given-names></name><name><surname>Tejón</surname><given-names>G</given-names></name><name><surname>Osorio-Barrios</surname><given-names>F</given-names></name><name><surname>Manríquez</surname><given-names>V</given-names></name><name><surname>Reyes</surname><given-names>P</given-names></name><name><surname>Pacheco</surname><given-names>R</given-names></name><name><surname>Bono</surname><given-names>MR</given-names></name><name><surname>Loyola</surname><given-names>A</given-names></name><name><surname>Rosemblatt</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The histone demethylase inhibitor GSK-J4 limits inflammation through the induction of a tolerogenic phenotype on DCs</article-title><source>Journal of Autoimmunity</source><volume>75</volume><fpage>105</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2016.07.011</pub-id><pub-id pub-id-type="pmid">27528513</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>P</given-names></name><name><surname>Nahrendorf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Monocytes in myocardial infarction</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>35</volume><fpage>1066</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.114.304652</pub-id><pub-id pub-id-type="pmid">25792449</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrchen</surname><given-names>JM</given-names></name><name><surname>Sunderkötter</surname><given-names>C</given-names></name><name><surname>Foell</surname><given-names>D</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer</article-title><source>Journal of Leukocyte Biology</source><volume>86</volume><fpage>557</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1189/jlb.1008647</pub-id><pub-id pub-id-type="pmid">19451397</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fassl</surname><given-names>SK</given-names></name><name><surname>Austermann</surname><given-names>J</given-names></name><name><surname>Papantonopoulou</surname><given-names>O</given-names></name><name><surname>Riemenschneider</surname><given-names>M</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name><name><surname>Bertheloot</surname><given-names>D</given-names></name><name><surname>Freise</surname><given-names>N</given-names></name><name><surname>Spiekermann</surname><given-names>C</given-names></name><name><surname>Witten</surname><given-names>A</given-names></name><name><surname>Viemann</surname><given-names>D</given-names></name><name><surname>Kirschnek</surname><given-names>S</given-names></name><name><surname>Stoll</surname><given-names>M</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Transcriptome assessment reveals a dominant role for TLR4 in the activation of human monocytes by the alarmin MRP8</article-title><source>Journal of Immunology (Baltimore, Md</source><volume>194</volume><fpage>575</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1401085</pub-id><pub-id pub-id-type="pmid">25505274</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foell</surname><given-names>D</given-names></name><name><surname>Frosch</surname><given-names>M</given-names></name><name><surname>Sorg</surname><given-names>C</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation</article-title><source>Clinica Chimica Acta; International Journal of Clinical Chemistry</source><volume>344</volume><fpage>37</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.cccn.2004.02.023</pub-id><pub-id pub-id-type="pmid">15149869</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foell</surname><given-names>D</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Proinflammatory S100 proteins in arthritis and autoimmune disease</article-title><source>Arthritis and Rheumatism</source><volume>50</volume><fpage>3762</fpage><lpage>3771</lpage><pub-id pub-id-type="doi">10.1002/art.20631</pub-id><pub-id pub-id-type="pmid">15593206</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frangogiannis</surname><given-names>NG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>S100A8/A9 as a therapeutic target in myocardial infarction: cellular mechanisms, molecular interactions, and translational challenges</article-title><source>European Heart Journal</source><volume>40</volume><fpage>2724</fpage><lpage>2726</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehz524</pub-id><pub-id pub-id-type="pmid">31334753</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freise</surname><given-names>N</given-names></name><name><surname>Burghard</surname><given-names>A</given-names></name><name><surname>Ortkras</surname><given-names>T</given-names></name><name><surname>Daber</surname><given-names>N</given-names></name><name><surname>Imam Chasan</surname><given-names>A</given-names></name><name><surname>Jauch</surname><given-names>S-L</given-names></name><name><surname>Fehler</surname><given-names>O</given-names></name><name><surname>Hillebrand</surname><given-names>J</given-names></name><name><surname>Schakaki</surname><given-names>M</given-names></name><name><surname>Rojas</surname><given-names>J</given-names></name><name><surname>Grimbacher</surname><given-names>B</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Hoffmeier</surname><given-names>A</given-names></name><name><surname>Martens</surname><given-names>S</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Austermann</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Signaling mechanisms inducing hyporesponsiveness of phagocytes during systemic inflammation</article-title><source>Blood</source><volume>134</volume><fpage>134</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1182/blood.2019000320</pub-id><pub-id pub-id-type="pmid">31076441</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Efficient isolation of specific genomic regions and identification of associated proteins by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP) using CRISPR</article-title><source>Biochemical and Biophysical Research Communications</source><volume>439</volume><fpage>132</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2013.08.013</pub-id><pub-id pub-id-type="pmid">23942116</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiu</surname><given-names>K</given-names></name><name><surname>Manabe</surname><given-names>I</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice</article-title><source>The Journal of Clinical Investigation</source><volume>121</volume><fpage>3425</fpage><lpage>3441</lpage><pub-id pub-id-type="doi">10.1172/JCI57582</pub-id><pub-id pub-id-type="pmid">21821915</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabe</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>AliBaba2: context specific identification of transcription factor binding sites</article-title><source>In Silico Biology</source><volume>2</volume><fpage>S1</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">11808873</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gran</surname><given-names>S</given-names></name><name><surname>Honold</surname><given-names>L</given-names></name><name><surname>Fehler</surname><given-names>O</given-names></name><name><surname>Zenker</surname><given-names>S</given-names></name><name><surname>Eligehausen</surname><given-names>S</given-names></name><name><surname>Kuhlmann</surname><given-names>MT</given-names></name><name><surname>Geven</surname><given-names>E</given-names></name><name><surname>van den Bosch</surname><given-names>M</given-names></name><name><surname>van Lent</surname><given-names>P</given-names></name><name><surname>Spiekermann</surname><given-names>C</given-names></name><name><surname>Hermann</surname><given-names>S</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Schäfers</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Imaging, myeloid precursor immortalization, and genome editing for defining mechanisms of leukocyte recruitment <italic>in vivo</italic></article-title><source>Theranostics</source><volume>8</volume><fpage>2407</fpage><lpage>2423</lpage><pub-id pub-id-type="doi">10.7150/thno.23632</pub-id><pub-id pub-id-type="pmid">29721088</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>T-Y</given-names></name><name><surname>Chang</surname><given-names>K-A</given-names></name><name><surname>Kim</surname><given-names>J a</given-names></name><name><surname>Kim</surname><given-names>H-S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Chong</surname><given-names>YH</given-names></name><name><surname>Suh</surname><given-names>Y-H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>S100a9 knockdown decreases the memory impairment and the neuropathology in Tg2576 mice, AD animal model</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e8840</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0008840</pub-id><pub-id pub-id-type="pmid">20098622</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heming</surname><given-names>M</given-names></name><name><surname>Gran</surname><given-names>S</given-names></name><name><surname>Jauch</surname><given-names>S-L</given-names></name><name><surname>Fischer-Riepe</surname><given-names>L</given-names></name><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Klotz</surname><given-names>L</given-names></name><name><surname>Hermann</surname><given-names>S</given-names></name><name><surname>Schäfers</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Barczyk-Kahlert</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Peroxisome Proliferator-Activated Receptor-γ Modulates the Response of Macrophages to Lipopolysaccharide and Glucocorticoids</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>893</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00893</pub-id><pub-id pub-id-type="pmid">29867927</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hessian</surname><given-names>PA</given-names></name><name><surname>Edgeworth</surname><given-names>J</given-names></name><name><surname>Hogg</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes</article-title><source>Journal of Leukocyte Biology</source><volume>53</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">8445331</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Long</surname><given-names>F</given-names></name><name><surname>Di</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhun Zhu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Jmjd3 regulates inflammasome activation and aggravates DSS-induced colitis in mice</article-title><source>FASEB Journal</source><volume>34</volume><fpage>4107</fpage><lpage>4119</lpage><pub-id pub-id-type="doi">10.1096/fj.201902200RR</pub-id><pub-id pub-id-type="pmid">31971317</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Qin</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Long</surname><given-names>F</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>YZ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Histone demethylase JMJD3 regulates fibroblast-like synoviocyte-mediated proliferation and joint destruction in rheumatoid arthritis</article-title><source>FASEB Journal</source><volume>32</volume><fpage>4031</fpage><lpage>4042</lpage><pub-id pub-id-type="doi">10.1096/fj.201701483R</pub-id><pub-id pub-id-type="pmid">29481307</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joung</surname><given-names>J</given-names></name><name><surname>Konermann</surname><given-names>S</given-names></name><name><surname>Gootenberg</surname><given-names>JS</given-names></name><name><surname>Abudayyeh</surname><given-names>OO</given-names></name><name><surname>Platt</surname><given-names>RJ</given-names></name><name><surname>Brigham</surname><given-names>MD</given-names></name><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening</article-title><source>Nature Protocols</source><volume>12</volume><fpage>828</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1038/nprot.2017.016</pub-id><pub-id pub-id-type="pmid">28333914</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>A</given-names></name><name><surname>Fahed</surname><given-names>AC</given-names></name><name><surname>Shibbani</surname><given-names>K</given-names></name><name><surname>El-Hachem</surname><given-names>N</given-names></name><name><surname>Bou-Slaiman</surname><given-names>S</given-names></name><name><surname>Arabi</surname><given-names>M</given-names></name><name><surname>Kurban</surname><given-names>M</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Haidar</surname><given-names>R</given-names></name><name><surname>Baydoun</surname><given-names>E</given-names></name><name><surname>Nemer</surname><given-names>G</given-names></name><name><surname>Bitar</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A Novel Role for <italic>CSRP1</italic> in A Lebanese Family with Congenital Cardiac Defects</article-title><source>Frontiers in Genetics</source><volume>8</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.3389/fgene.2017.00217</pub-id><pub-id pub-id-type="pmid">29326753</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kehl-Fie</surname><given-names>TE</given-names></name><name><surname>Skaar</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Nutritional immunity beyond iron: a role for manganese and zinc</article-title><source>Current Opinion in Chemical Biology</source><volume>14</volume><fpage>218</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2009.11.008</pub-id><pub-id pub-id-type="pmid">20015678</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kehl-Fie</surname><given-names>TE</given-names></name><name><surname>Chitayat</surname><given-names>S</given-names></name><name><surname>Hood</surname><given-names>MI</given-names></name><name><surname>Damo</surname><given-names>S</given-names></name><name><surname>Restrepo</surname><given-names>N</given-names></name><name><surname>Garcia</surname><given-names>C</given-names></name><name><surname>Munro</surname><given-names>KA</given-names></name><name><surname>Chazin</surname><given-names>WJ</given-names></name><name><surname>Skaar</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Nutrient metal sequestration by calprotectin inhibits bacterial superoxide defense, enhancing neutrophil killing of <italic>Staphylococcus aureus</italic></article-title><source>Cell Host &amp; Microbe</source><volume>10</volume><fpage>158</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2011.07.004</pub-id><pub-id pub-id-type="pmid">21843872</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Kelley</surname><given-names>R</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions</article-title><source>Genome Biology</source><volume>14</volume><elocation-id>R36</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2013-14-4-r36</pub-id><pub-id pub-id-type="pmid">23618408</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Paggi</surname><given-names>JM</given-names></name><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Bennett</surname><given-names>C</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype</article-title><source>Nature Biotechnology</source><volume>37</volume><fpage>907</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0201-4</pub-id><pub-id pub-id-type="pmid">31375807</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>CY</given-names></name><name><surname>Chang</surname><given-names>LH</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Sterneck</surname><given-names>E</given-names></name><name><surname>Cheng</surname><given-names>CP</given-names></name><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Huang</surname><given-names>AM</given-names></name><name><surname>Tseng</surname><given-names>JT</given-names></name><name><surname>Wang</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>CCAAT/enhancer binding protein delta (CEBPD) elevating PTX3 expression inhibits macrophage-mediated phagocytosis of dying neuron cells</article-title><source>Neurobiology of Aging</source><volume>33</volume><elocation-id>422</elocation-id><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2010.09.017</pub-id><pub-id pub-id-type="pmid">21112127</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruidenier</surname><given-names>L</given-names></name><name><surname>Chung</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Liddle</surname><given-names>J</given-names></name><name><surname>Che</surname><given-names>K</given-names></name><name><surname>Joberty</surname><given-names>G</given-names></name><name><surname>Bantscheff</surname><given-names>M</given-names></name><name><surname>Bountra</surname><given-names>C</given-names></name><name><surname>Bridges</surname><given-names>A</given-names></name><name><surname>Diallo</surname><given-names>H</given-names></name><name><surname>Eberhard</surname><given-names>D</given-names></name><name><surname>Hutchinson</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>E</given-names></name><name><surname>Katso</surname><given-names>R</given-names></name><name><surname>Leveridge</surname><given-names>M</given-names></name><name><surname>Mander</surname><given-names>PK</given-names></name><name><surname>Mosley</surname><given-names>J</given-names></name><name><surname>Ramirez-Molina</surname><given-names>C</given-names></name><name><surname>Rowland</surname><given-names>P</given-names></name><name><surname>Schofield</surname><given-names>CJ</given-names></name><name><surname>Sheppard</surname><given-names>RJ</given-names></name><name><surname>Smith</surname><given-names>JE</given-names></name><name><surname>Swales</surname><given-names>C</given-names></name><name><surname>Tanner</surname><given-names>R</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Tumber</surname><given-names>A</given-names></name><name><surname>Drewes</surname><given-names>G</given-names></name><name><surname>Oppermann</surname><given-names>U</given-names></name><name><surname>Patel</surname><given-names>DJ</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Wilson</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response</article-title><source>Nature</source><volume>488</volume><fpage>404</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1038/nature11262</pub-id><pub-id pub-id-type="pmid">22842901</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kummer</surname><given-names>MP</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Axt</surname><given-names>D</given-names></name><name><surname>Griep</surname><given-names>A</given-names></name><name><surname>Vieira-Saecker</surname><given-names>A</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Heneka</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mrp14 deficiency ameliorates amyloid β burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing</article-title><source>The Journal of Neuroscience</source><volume>32</volume><fpage>17824</fpage><lpage>17829</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1504-12.2012</pub-id><pub-id pub-id-type="pmid">23223301</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuruto-Niwa</surname><given-names>R</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Takeishi</surname><given-names>K</given-names></name><name><surname>Nozawa</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Transcriptional regulation by C/EBP alpha and -beta in the expression of the gene for the MRP14 myeloid calcium binding protein</article-title><source>Cell Structure and Function</source><volume>23</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1247/csf.23.109</pub-id><pub-id pub-id-type="pmid">9706399</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kweon</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>High-throughput genetic screens using CRISPR-Cas9 system</article-title><source>Archives of Pharmacal Research</source><volume>41</volume><fpage>875</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1007/s12272-018-1029-z</pub-id><pub-id pub-id-type="pmid">29637495</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>P-H</given-names></name><name><surname>Wang</surname><given-names>W-L</given-names></name><name><surname>Ko</surname><given-names>C-Y</given-names></name><name><surname>Lee</surname><given-names>Y-C</given-names></name><name><surname>Yang</surname><given-names>W-M</given-names></name><name><surname>Shen</surname><given-names>T-W</given-names></name><name><surname>Chang</surname><given-names>W-C</given-names></name><name><surname>Wang</surname><given-names>J-M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>HDAC1/HDAC3 modulates PPARG2 transcription through the sumoylated CEBPD in hepatic lipogenesis</article-title><source>Biochimica et Biophysica Acta</source><volume>1783</volume><fpage>1803</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2008.06.008</pub-id><pub-id pub-id-type="pmid">18619497</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>F</given-names></name><name><surname>Bayliss</surname><given-names>PE</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Whetstine</surname><given-names>JR</given-names></name><name><surname>Wang</surname><given-names>JK</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Iwase</surname><given-names>S</given-names></name><name><surname>Alpatov</surname><given-names>R</given-names></name><name><surname>Issaeva</surname><given-names>I</given-names></name><name><surname>Canaani</surname><given-names>E</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A histone H3 lysine 27 demethylase regulates animal posterior development</article-title><source>Nature</source><volume>449</volume><fpage>689</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1038/nature06192</pub-id><pub-id pub-id-type="pmid">17851529</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>X-O</given-names></name><name><surname>Wang</surname><given-names>H-X</given-names></name><name><surname>Qi</surname><given-names>R-Q</given-names></name><name><surname>Xu</surname><given-names>Y-Y</given-names></name><name><surname>Yu</surname><given-names>Y-J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>X-H</given-names></name><name><surname>Geng</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Shikonin inhibits CEBPD downregulation in IL‑17‑treated HaCaT cells and in an imiquimod‑induced psoriasis model</article-title><source>Molecular Medicine Reports</source><volume>22</volume><fpage>2263</fpage><lpage>2272</lpage><pub-id pub-id-type="doi">10.3892/mmr.2020.11315</pub-id><pub-id pub-id-type="pmid">32705251</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>M</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Pagès</surname><given-names>H</given-names></name><name><surname>Aboyoun</surname><given-names>P</given-names></name><name><surname>Carlson</surname><given-names>M</given-names></name><name><surname>Gentleman</surname><given-names>R</given-names></name><name><surname>Morgan</surname><given-names>MT</given-names></name><name><surname>Carey</surname><given-names>VJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Software for computing and annotating genomic ranges</article-title><source>PLOS Computational Biology</source><volume>9</volume><elocation-id>118</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003118</pub-id><pub-id pub-id-type="pmid">23950696</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>J-K</given-names></name><name><surname>Choi</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>C-S</given-names></name><name><surname>Sim</surname><given-names>JH</given-names></name><name><surname>Cho</surname><given-names>C-H</given-names></name><name><surname>Lee</surname><given-names>K-H</given-names></name><name><surname>Cho</surname><given-names>I-H</given-names></name><name><surname>Chung</surname><given-names>M-H</given-names></name><name><surname>Kim</surname><given-names>H-R</given-names></name><name><surname>Ye</surname><given-names>S-K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Interleukin-6 induces S100A9 expression in colonic epithelial cells through STAT3 activation in experimental ulcerative colitis</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e38801</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0038801</pub-id><pub-id pub-id-type="pmid">22962574</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leukert</surname><given-names>N</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Strupat</surname><given-names>K</given-names></name><name><surname>Reichelt</surname><given-names>R</given-names></name><name><surname>Sorg</surname><given-names>C</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity</article-title><source>Journal of Molecular Biology</source><volume>359</volume><fpage>961</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2006.04.009</pub-id><pub-id pub-id-type="pmid">16690079</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Strohmeyer</surname><given-names>R</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Lue</surname><given-names>L-F</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>CCAAT/enhancer binding protein delta (C/EBPdelta) expression and elevation in Alzheimer’s disease</article-title><source>Neurobiology of Aging</source><volume>25</volume><fpage>991</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2003.10.016</pub-id><pub-id pub-id-type="pmid">15212823</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Cong</surname><given-names>L</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Liu</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>554</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0554-4</pub-id><pub-id pub-id-type="pmid">25476604</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Jiao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Qiao</surname><given-names>B</given-names></name><name><surname>Bond Lau</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>X-L</given-names></name><name><surname>Du</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>S100a8/a9 Signaling Causes Mitochondrial Dysfunction and Cardiomyocyte Death in Response to Ischemic/Reperfusion Injury</article-title><source>Circulation</source><volume>140</volume><fpage>751</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.039262</pub-id><pub-id pub-id-type="pmid">31220942</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litvak</surname><given-names>V</given-names></name><name><surname>Ramsey</surname><given-names>SA</given-names></name><name><surname>Rust</surname><given-names>AG</given-names></name><name><surname>Zak</surname><given-names>DE</given-names></name><name><surname>Kennedy</surname><given-names>KA</given-names></name><name><surname>Lampano</surname><given-names>AE</given-names></name><name><surname>Nykter</surname><given-names>M</given-names></name><name><surname>Shmulevich</surname><given-names>I</given-names></name><name><surname>Aderem</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals</article-title><source>Nature Immunology</source><volume>10</volume><fpage>437</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/ni.1721</pub-id><pub-id pub-id-type="pmid">19270711</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y-W</given-names></name><name><surname>Tseng</surname><given-names>H-P</given-names></name><name><surname>Chen</surname><given-names>L-C</given-names></name><name><surname>Chen</surname><given-names>B-K</given-names></name><name><surname>Chang</surname><given-names>W-C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Functional cooperation of simian virus 40 promoter factor 1 and CCAAT/enhancer-binding protein beta and delta in lipopolysaccharide-induced gene activation of IL-10 in mouse macrophages</article-title><source>Journal of Immunology (Baltimore, Md</source><volume>171</volume><fpage>821</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.2.821</pub-id><pub-id pub-id-type="pmid">12847250</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y-F</given-names></name><name><surname>Wei</surname><given-names>J-Y</given-names></name><name><surname>Shi</surname><given-names>M-H</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Glucocorticoid Induces Hepatic Steatosis by Inhibiting Activating Transcription Factor 3 (ATF3)/S100A9 Protein Signaling in Granulocytic Myeloid-derived Suppressor Cells</article-title><source>The Journal of Biological Chemistry</source><volume>291</volume><fpage>21771</fpage><lpage>21785</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.726364</pub-id><pub-id pub-id-type="pmid">27573240</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenz</surname><given-names>E</given-names></name><name><surname>Muhlebach</surname><given-names>MS</given-names></name><name><surname>Tessier</surname><given-names>PA</given-names></name><name><surname>Alexis</surname><given-names>NE</given-names></name><name><surname>Duncan Hite</surname><given-names>R</given-names></name><name><surname>Seeds</surname><given-names>MC</given-names></name><name><surname>Peden</surname><given-names>DB</given-names></name><name><surname>Meredith</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases</article-title><source>Respiratory Medicine</source><volume>102</volume><fpage>567</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2007.11.011</pub-id><pub-id pub-id-type="pmid">18164192</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loser</surname><given-names>K</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Voskort</surname><given-names>M</given-names></name><name><surname>Lueken</surname><given-names>A</given-names></name><name><surname>Kupas</surname><given-names>V</given-names></name><name><surname>Nacken</surname><given-names>W</given-names></name><name><surname>Klenner</surname><given-names>L</given-names></name><name><surname>Kuhn</surname><given-names>A</given-names></name><name><surname>Foell</surname><given-names>D</given-names></name><name><surname>Sorokin</surname><given-names>L</given-names></name><name><surname>Luger</surname><given-names>TA</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Beissert</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells</article-title><source>Nature Medicine</source><volume>16</volume><fpage>713</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1038/nm.2150</pub-id><pub-id pub-id-type="pmid">20473308</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>TZ</given-names></name><name><surname>Simard</surname><given-names>FA</given-names></name><name><surname>Cloutier</surname><given-names>A</given-names></name><name><surname>Vardhan</surname><given-names>H</given-names></name><name><surname>Dubois</surname><given-names>CM</given-names></name><name><surname>McDonald</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The p38-MSK1 signaling cascade influences cytokine production through CREB and C/EBP factors in human neutrophils</article-title><source>Journal of Immunology (Baltimore, Md</source><volume>191</volume><fpage>4299</fpage><lpage>4307</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1301117</pub-id><pub-id pub-id-type="pmid">24038085</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meugnier</surname><given-names>E</given-names></name><name><surname>Coury</surname><given-names>F</given-names></name><name><surname>Tebib</surname><given-names>J</given-names></name><name><surname>Ferraro-Peyret</surname><given-names>C</given-names></name><name><surname>Rome</surname><given-names>S</given-names></name><name><surname>Bienvenu</surname><given-names>J</given-names></name><name><surname>Vidal</surname><given-names>H</given-names></name><name><surname>Sibilia</surname><given-names>J</given-names></name><name><surname>Fabien</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-alpha treatments</article-title><source>Physiological Genomics</source><volume>43</volume><fpage>365</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1152/physiolgenomics.00127.2010</pub-id><pub-id pub-id-type="pmid">21266503</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moncrieffe</surname><given-names>H</given-names></name><name><surname>Ursu</surname><given-names>S</given-names></name><name><surname>Holzinger</surname><given-names>D</given-names></name><name><surname>Patrick</surname><given-names>F</given-names></name><name><surname>Kassoumeri</surname><given-names>L</given-names></name><name><surname>Wade</surname><given-names>A</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Wedderburn</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein</article-title><source>Rheumatology (Oxford, England)</source><volume>52</volume><fpage>1467</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/ket152</pub-id><pub-id pub-id-type="pmid">23620557</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Na</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Na</surname><given-names>W</given-names></name><name><surname>Shin</surname><given-names>J-Y</given-names></name><name><surname>Lee</surname><given-names>M-J</given-names></name><name><surname>Yune</surname><given-names>TY</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Jung</surname><given-names>H-S</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><name><surname>Ju</surname><given-names>B-G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Histone H3K27 Demethylase JMJD3 in Cooperation with NF-κB Regulates Keratinocyte Wound Healing</article-title><source>The Journal of Investigative Dermatology</source><volume>136</volume><fpage>847</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2015.11.029</pub-id><pub-id pub-id-type="pmid">26802933</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Na</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>JY</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>BJ</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><name><surname>Yune</surname><given-names>TY</given-names></name><name><surname>Ju</surname><given-names>B-G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>JMJD3 and NF-κB-dependent activation of Notch1 gene is required for keratinocyte migration during skin wound healing</article-title><source>Scientific Reports</source><volume>7</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41598-017-06750-7</pub-id><pub-id pub-id-type="pmid">28747631</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nahrendorf</surname><given-names>M</given-names></name><name><surname>Swirski</surname><given-names>FK</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name><name><surname>Stangenberg</surname><given-names>L</given-names></name><name><surname>Wurdinger</surname><given-names>T</given-names></name><name><surname>Figueiredo</surname><given-names>J-L</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions</article-title><source>The Journal of Experimental Medicine</source><volume>204</volume><fpage>3037</fpage><lpage>3047</lpage><pub-id pub-id-type="doi">10.1084/jem.20070885</pub-id><pub-id pub-id-type="pmid">18025128</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishioka</surname><given-names>K</given-names></name><name><surname>Ohshima</surname><given-names>S</given-names></name><name><surname>Umeshita-Sasai</surname><given-names>M</given-names></name><name><surname>Yamaguchi</surname><given-names>N</given-names></name><name><surname>Mima</surname><given-names>T</given-names></name><name><surname>Nomura</surname><given-names>S</given-names></name><name><surname>Murata</surname><given-names>N</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Miyake</surname><given-names>T</given-names></name><name><surname>Yoshizaki</surname><given-names>K</given-names></name><name><surname>Suemura</surname><given-names>M</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name><name><surname>Saeki</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Enhanced expression and DNA binding activity of two CCAAT/enhancer-binding protein isoforms, C/EBPbeta and C/EBPdelta, in rheumatoid synovium</article-title><source>Arthritis and Rheumatism</source><volume>43</volume><fpage>1591</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(200007)43:7&lt;1591::AID-ANR24&gt;3.0.CO;2-9</pub-id><pub-id pub-id-type="pmid">10902764</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Shalem</surname><given-names>O</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Improved vectors and genome-wide libraries for CRISPR screening</article-title><source>Nature Methods</source><volume>11</volume><fpage>783</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3047</pub-id><pub-id pub-id-type="pmid">25075903</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalem</surname><given-names>O</given-names></name><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Hartenian</surname><given-names>E</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Mikkelson</surname><given-names>T</given-names></name><name><surname>Heckl</surname><given-names>D</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genome-scale CRISPR-Cas9 knockout screening in human cells</article-title><source>Science (New York, N.Y.)</source><volume>343</volume><fpage>84</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1126/science.1247005</pub-id><pub-id pub-id-type="pmid">24336571</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>CE</given-names></name><name><surname>Goyette</surname><given-names>J</given-names></name><name><surname>Utter</surname><given-names>V</given-names></name><name><surname>Rahimi</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Geczy</surname><given-names>CL</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inflammatory S100A9 and S100A12 proteins in Alzheimer’s disease</article-title><source>Neurobiology of Aging</source><volume>27</volume><fpage>1554</fpage><lpage>1563</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.09.033</pub-id><pub-id pub-id-type="pmid">16253391</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sreejit</surname><given-names>G</given-names></name><name><surname>Abdel-Latif</surname><given-names>A</given-names></name><name><surname>Athmanathan</surname><given-names>B</given-names></name><name><surname>Annabathula</surname><given-names>R</given-names></name><name><surname>Dhyani</surname><given-names>A</given-names></name><name><surname>Noothi</surname><given-names>SK</given-names></name><name><surname>Quaife-Ryan</surname><given-names>GA</given-names></name><name><surname>Al-Sharea</surname><given-names>A</given-names></name><name><surname>Pernes</surname><given-names>G</given-names></name><name><surname>Dragoljevic</surname><given-names>D</given-names></name><name><surname>Lal</surname><given-names>H</given-names></name><name><surname>Schroder</surname><given-names>K</given-names></name><name><surname>Hanaoka</surname><given-names>BY</given-names></name><name><surname>Raman</surname><given-names>C</given-names></name><name><surname>Grant</surname><given-names>MB</given-names></name><name><surname>Hudson</surname><given-names>JE</given-names></name><name><surname>Smyth</surname><given-names>SS</given-names></name><name><surname>Porrello</surname><given-names>ER</given-names></name><name><surname>Murphy</surname><given-names>AJ</given-names></name><name><surname>Nagareddy</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neutrophil-Derived S100A8/A9 Amplify Granulopoiesis After Myocardial Infarction</article-title><source>Circulation</source><volume>141</volume><fpage>1080</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.043833</pub-id><pub-id pub-id-type="pmid">31941367</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sterneck</surname><given-names>E</given-names></name><name><surname>Paylor</surname><given-names>R</given-names></name><name><surname>Jackson-Lewis</surname><given-names>V</given-names></name><name><surname>Libbey</surname><given-names>M</given-names></name><name><surname>Przedborski</surname><given-names>S</given-names></name><name><surname>Tessarollo</surname><given-names>L</given-names></name><name><surname>Crawley</surname><given-names>JN</given-names></name><name><surname>Johnson</surname><given-names>PF</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Selectively enhanced contextual fear conditioning in mice lacking the transcriptional regulator CCAAT/enhancer binding protein delta</article-title><source>PNAS</source><volume>95</volume><fpage>10908</fpage><lpage>10913</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.18.10908</pub-id><pub-id pub-id-type="pmid">9724803</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>JT</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration</article-title><source>Briefings in Bioinformatics</source><volume>14</volume><fpage>178</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1093/bib/bbs017</pub-id><pub-id pub-id-type="pmid">22517427</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Lent</surname><given-names>PLEM</given-names></name><name><surname>Grevers</surname><given-names>L</given-names></name><name><surname>Blom</surname><given-names>AB</given-names></name><name><surname>Sloetjes</surname><given-names>A</given-names></name><name><surname>Mort</surname><given-names>JS</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Nacken</surname><given-names>W</given-names></name><name><surname>van den Berg</surname><given-names>WB</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis</article-title><source>Annals of the Rheumatic Diseases</source><volume>67</volume><fpage>1750</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1136/ard.2007.077800</pub-id><pub-id pub-id-type="pmid">18055478</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Lent</surname><given-names>PLEM</given-names></name><name><surname>Blom</surname><given-names>AB</given-names></name><name><surname>Schelbergen</surname><given-names>RFP</given-names></name><name><surname>Slöetjes</surname><given-names>A</given-names></name><name><surname>Lafeber</surname><given-names>FPJG</given-names></name><name><surname>Lems</surname><given-names>WF</given-names></name><name><surname>Cats</surname><given-names>H</given-names></name><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>van den Berg</surname><given-names>WB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis</article-title><source>Arthritis and Rheumatism</source><volume>64</volume><fpage>1466</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.1002/art.34315</pub-id><pub-id pub-id-type="pmid">22143922</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Tenbrock</surname><given-names>K</given-names></name><name><surname>Ludwig</surname><given-names>S</given-names></name><name><surname>Leukert</surname><given-names>N</given-names></name><name><surname>Ehrhardt</surname><given-names>C</given-names></name><name><surname>van Zoelen</surname><given-names>MAD</given-names></name><name><surname>Nacken</surname><given-names>W</given-names></name><name><surname>Foell</surname><given-names>D</given-names></name><name><surname>van der Poll</surname><given-names>T</given-names></name><name><surname>Sorg</surname><given-names>C</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock</article-title><source>Nature Medicine</source><volume>13</volume><fpage>1042</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1038/nm1638</pub-id><pub-id pub-id-type="pmid">17767165</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Eisenblätter</surname><given-names>M</given-names></name><name><surname>Völler</surname><given-names>T</given-names></name><name><surname>Zenker</surname><given-names>S</given-names></name><name><surname>Hermann</surname><given-names>S</given-names></name><name><surname>van Lent</surname><given-names>P</given-names></name><name><surname>Faust</surname><given-names>A</given-names></name><name><surname>Geyer</surname><given-names>C</given-names></name><name><surname>Petersen</surname><given-names>B</given-names></name><name><surname>Roebrock</surname><given-names>K</given-names></name><name><surname>Schäfers</surname><given-names>M</given-names></name><name><surname>Bremer</surname><given-names>C</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity</article-title><source>Nature Communications</source><volume>5</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/ncomms5593</pub-id><pub-id pub-id-type="pmid">25098555</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Stratis</surname><given-names>A</given-names></name><name><surname>Wixler</surname><given-names>V</given-names></name><name><surname>Völler</surname><given-names>T</given-names></name><name><surname>Thurainayagam</surname><given-names>S</given-names></name><name><surname>Jorch</surname><given-names>SK</given-names></name><name><surname>Zenker</surname><given-names>S</given-names></name><name><surname>Dreiling</surname><given-names>A</given-names></name><name><surname>Chakraborty</surname><given-names>D</given-names></name><name><surname>Fröhling</surname><given-names>M</given-names></name><name><surname>Paruzel</surname><given-names>P</given-names></name><name><surname>Wehmeyer</surname><given-names>C</given-names></name><name><surname>Hermann</surname><given-names>S</given-names></name><name><surname>Papantonopoulou</surname><given-names>O</given-names></name><name><surname>Geyer</surname><given-names>C</given-names></name><name><surname>Loser</surname><given-names>K</given-names></name><name><surname>Schäfers</surname><given-names>M</given-names></name><name><surname>Ludwig</surname><given-names>S</given-names></name><name><surname>Stoll</surname><given-names>M</given-names></name><name><surname>Leanderson</surname><given-names>T</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>König</surname><given-names>S</given-names></name><name><surname>Pap</surname><given-names>T</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Autoinhibitory regulation of S100A8/S100A9 alarmin activity locally restricts sterile inflammation</article-title><source>The Journal of Clinical Investigation</source><volume>128</volume><fpage>1852</fpage><lpage>1866</lpage><pub-id pub-id-type="doi">10.1172/JCI89867</pub-id><pub-id pub-id-type="pmid">29611822</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadleigh</surname><given-names>DJ</given-names></name><name><surname>Reddy</surname><given-names>ST</given-names></name><name><surname>Kopp</surname><given-names>E</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Herschman</surname><given-names>HR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>6259</fpage><lpage>6266</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.9.6259</pub-id><pub-id pub-id-type="pmid">10692422</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GG</given-names></name><name><surname>Calvo</surname><given-names>KR</given-names></name><name><surname>Pasillas</surname><given-names>MP</given-names></name><name><surname>Sykes</surname><given-names>DB</given-names></name><name><surname>Häcker</surname><given-names>H</given-names></name><name><surname>Kamps</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2006">2006a</year><article-title>Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8</article-title><source>Nature Methods</source><volume>3</volume><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/nmeth865</pub-id><pub-id pub-id-type="pmid">16554834</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JM</given-names></name><name><surname>Ko</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>LC</given-names></name><name><surname>Wang</surname><given-names>WL</given-names></name><name><surname>Chang</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2006">2006b</year><article-title>Functional role of NF-IL6beta and its sumoylation and acetylation modifications in promoter activation of cyclooxygenase 2 gene</article-title><source>Nucleic Acids Research</source><volume>34</volume><fpage>217</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1093/nar/gkj422</pub-id><pub-id pub-id-type="pmid">16397300</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Ozer</surname><given-names>HG</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Urabe</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Kent</surname><given-names>KC</given-names></name><name><surname>Guo</surname><given-names>L-W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A hierarchical and collaborative BRD4/CEBPD partnership governs vascular smooth muscle cell inflammation</article-title><source>Molecular Therapy. Methods &amp; Clinical Development</source><volume>21</volume><fpage>54</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2021.02.021</pub-id><pub-id pub-id-type="pmid">33768129</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiddon</surname><given-names>JL</given-names></name><name><surname>Langford</surname><given-names>AT</given-names></name><name><surname>Wong</surname><given-names>C-J</given-names></name><name><surname>Zhong</surname><given-names>JW</given-names></name><name><surname>Tapscott</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Conservation and innovation in the DUX4-family gene network</article-title><source>Nature Genetics</source><volume>49</volume><fpage>935</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1038/ng.3846</pub-id><pub-id pub-id-type="pmid">28459454</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witten</surname><given-names>A</given-names></name><name><surname>Martens</surname><given-names>L</given-names></name><name><surname>Schäfer</surname><given-names>A-C</given-names></name><name><surname>Troidl</surname><given-names>C</given-names></name><name><surname>Pankuweit</surname><given-names>S</given-names></name><name><surname>Vlacil</surname><given-names>A-K</given-names></name><name><surname>Oberoi</surname><given-names>R</given-names></name><name><surname>Schieffer</surname><given-names>B</given-names></name><name><surname>Grote</surname><given-names>K</given-names></name><name><surname>Stoll</surname><given-names>M</given-names></name><name><surname>Markus</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Monocyte subpopulation profiling indicates CDK6-derived cell differentiation and identifies subpopulation-specific miRNA expression sets in acute and stable coronary artery disease</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>5589</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-08600-7</pub-id><pub-id pub-id-type="pmid">35379829</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>JMJD3 is a histone H3K27 demethylase</article-title><source>Cell Research</source><volume>17</volume><fpage>850</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1038/cr.2007.83</pub-id><pub-id pub-id-type="pmid">17923864</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Milazzo</surname><given-names>JP</given-names></name><name><surname>Somerville</surname><given-names>TDD</given-names></name><name><surname>Tarumoto</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y-H</given-names></name><name><surname>Ostrander</surname><given-names>EL</given-names></name><name><surname>Wilkinson</surname><given-names>JE</given-names></name><name><surname>Challen</surname><given-names>GA</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia</article-title><source>Cancer Cell</source><volume>33</volume><fpage>13</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.12.002</pub-id><pub-id pub-id-type="pmid">29316427</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Kong</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>S100A8 and S100A9, both transcriptionally regulated by PU.1, promote epithelial-mesenchymal transformation (EMT) and invasive growth of dermal keratinocytes during scar formation post burn</article-title><source>Aging</source><volume>13</volume><fpage>15523</fpage><lpage>15537</lpage><pub-id pub-id-type="doi">10.18632/aging.203112</pub-id><pub-id pub-id-type="pmid">34099591</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>PF</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CCAAT/enhancer-binding protein δ is a critical mediator of lipopolysaccharide-induced acute lung injury</article-title><source>The American Journal of Pathology</source><volume>182</volume><fpage>420</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2012.10.013</pub-id><pub-id pub-id-type="pmid">23177475</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer</article-title><source>Oncogene</source><volume>36</volume><fpage>2969</fpage><lpage>2980</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.448</pub-id><pub-id pub-id-type="pmid">28092673</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zenz</surname><given-names>R</given-names></name><name><surname>Eferl</surname><given-names>R</given-names></name><name><surname>Scheinecker</surname><given-names>C</given-names></name><name><surname>Redlich</surname><given-names>K</given-names></name><name><surname>Smolen</surname><given-names>J</given-names></name><name><surname>Schonthaler</surname><given-names>HB</given-names></name><name><surname>Kenner</surname><given-names>L</given-names></name><name><surname>Tschachler</surname><given-names>E</given-names></name><name><surname>Wagner</surname><given-names>EF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease</article-title><source>Arthritis Research &amp; Therapy</source><volume>10</volume><elocation-id>201</elocation-id><pub-id pub-id-type="doi">10.1186/ar2338</pub-id><pub-id pub-id-type="pmid">18226189</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>S100a8</italic></td><td align="left" valign="bottom">NCBI</td><td align="left" valign="bottom">Gene ID:20201</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>S100a9</italic></td><td align="left" valign="bottom">NCBI</td><td align="left" valign="bottom">Gene ID:20202</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">Subcloning Efficiency DH5α Competent Cells</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 18265017</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td align="left" valign="bottom">pHrodo Red <italic>S. aureus</italic> Bioparticles Conjugate</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A10010</td><td align="left" valign="bottom">5 × 10<sup>6</sup> per 0.5 × 10<sup>6</sup> cells</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Cebpd<sup>tm1Pfj</sup>/Cebpd<sup>tm1Pfj</sup></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/9724803/">9724803</ext-link></td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:3606309">MGI:3606309</ext-link></td><td align="left" valign="bottom">Esta Sterneck (CCR, NIH, MD)</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">B6J.129(Cg)-Igs2<sup>tm1.1(CAG-cas9*)Mmw</sup>/J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">Stock# 028239 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:028239">IMSR_JAX:028239</ext-link></td><td align="left" valign="bottom">PMID:26178787</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">WT ER-Hoxb8 cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Cas9-expressing ER-Hoxb8 cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C/EBPδ KO ER-Hoxb8 cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0063">CVCL_0063</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">Cas9+PHF8 gRNA in WT ER-Hoxb8 cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">Cas9+CSRP1 gRNA in WT ER-Hoxb8 cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">Cas9+HAND1 gRNA in WT ER-Hoxb8 cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">Cas9+FBXW7 gRNA in WT ER-Hoxb8 cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">Cas9+ATF3 gRNA in WT ER-Hoxb8 cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">Cas9+STAT3 gRNA in WT ER-Hoxb8 cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">Cas9+KLF5 gRNA in WT ER-Hoxb8 cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">Cas9+IRF7 gRNA in WT ER-Hoxb8 cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">Cas9+C/EBPβ gRNA in WT ER-Hoxb8 cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">MSCV <italic>S100a8</italic> prom_GFP in HEK293T</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">MSCV <italic>S100a8</italic> s1 prom_GFP in HEK293T</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">MSCV <italic>S100a8</italic> s2 prom_GFP in HEK293T</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">MSCV <italic>S100a8</italic> s3 prom_GFP in HEK293T</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">MSCV <italic>S100a8</italic> s2+3 prom_GFP in HEK293T</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">MSCV <italic>S100a9</italic> prom_GFP in HEK293T</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">MSCV <italic>S100a9</italic> s1 prom_GFP in HEK293T</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">MSCV <italic>S100a9</italic> s2 prom_GFP in HEK293T</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">MSCV <italic>S100a9</italic> s3 prom_GFP in HEK293T</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">MSCV <italic>S100a9</italic> s4 prom_GFP in HEK293T</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">TRE_3xFlag-C/EBPδ in HEK293T</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="top">Transfected construct (<italic>synthetic</italic>)</td><td align="left" valign="bottom">TRE_ctrl in HEK293T</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="top">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Patient-derived PBMCs</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/35379829/">35379829</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">BioNRW Study</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse S100A8 (rabbit polyclonal)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25098555/">25098555</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">ELISA (1:460) WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse S100A9 (rabbit polyclonal)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25098555/">25098555</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">ELISA (1:2300) WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse S100A9-FITC (rabbit polyclonal)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">FACS (5 µg/ml)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Ly-6B.2 Alloantigen (7/4) (rat monoclonal)</td><td align="left" valign="bottom">BioRad</td><td align="left" valign="bottom">Cat# MCA771F, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_322951">AB_322951</ext-link></td><td align="left" valign="bottom">Flow cytometry (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Gr-1 (RB6-8C5) from hybridoma cells (recombinant monoclonal)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Flow cytometry (1:200) AG Zarbock (Department of Anesthesiology, UKM)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD11b-Pb (M1/70) (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101224, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_755986">AB_755986</ext-link></td><td align="left" valign="bottom">FACS (1:100)<break/>Flow cytometry (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Ly-6C-PE (HK1.4) (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 128008, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1186132">AB_1186132</ext-link></td><td align="left" valign="bottom">FACS (1:100)<break/>Flow cytometry (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-IgG2b, κ Isotype control- Pb(RTK4530) (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 400627, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493561">AB_493561</ext-link></td><td align="left" valign="bottom">Flow cytometry (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-IgG2c, κ Isotype control-PE (RTK4174) (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 400707, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_326573">AB_326573</ext-link></td><td align="left" valign="bottom">Flow cytometry (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GAPDH (14 C10) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 2118, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_561053">AB_561053</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-alpha/beta-Tubulin (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 2148, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2288042">AB_2288042</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-H3K27me<sub>3</sub> (C36B11) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 9733, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2616029">AB_2616029</ext-link></td><td align="left" valign="bottom">ChIP(3 µg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Normal IgG control (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 2729, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1031062">AB_1031062</ext-link></td><td align="left" valign="bottom">ChIP(3 µg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-H3K27ac (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab4729, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2118291">AB_2118291</ext-link></td><td align="left" valign="bottom">ChIP(3 µg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-FLAG M2 (mouse monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# F1804, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_262044">AB_262044</ext-link></td><td align="left" valign="bottom">ChIP(3 µg) WB (1:1500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IgG1 Isotype control (MOPC-21) (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 554121, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_395252">AB_395252</ext-link></td><td align="left" valign="bottom">ChIP(3 µg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Rabbit Immunoglobulins/HRP (goat polyclonal)</td><td align="left" valign="bottom">Agilent</td><td align="left" valign="bottom">Cat# P0448, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2617138">AB_2617138</ext-link></td><td align="left" valign="bottom">WB (1:4000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Mouse Immunoglobulins/ HRP (rabbit polyclonal)</td><td align="left" valign="bottom">Agilent</td><td align="left" valign="bottom">Cat# P0260, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2636929">AB_2636929</ext-link></td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD2-PE (RPA-2.10) (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 555327, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_395734">AB_395734</ext-link></td><td align="left" valign="bottom">FACS (1:20)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD14-APC (M5E2) (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 555399, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_398596">AB_398596</ext-link></td><td align="left" valign="bottom">FACS (1:20)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD15-PE (HI98) (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 555402, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_395802">AB_395802</ext-link></td><td align="left" valign="bottom">FACS (1:5)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD19-PE (HIB19) (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 555413, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_395813">AB_395813</ext-link></td><td align="left" valign="bottom">FACS (1:20)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD16-PE-Cy7 (3 G8) (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 557744, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_396850">AB_396850</ext-link></td><td align="left" valign="bottom">FACS (1:20)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD56-PE (MY31) (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 556647, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_396511">AB_396511</ext-link></td><td align="left" valign="bottom">FACS (1:5)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD335-PE (9E2/NKp46) (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 557991, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_396974">AB_396974</ext-link></td><td align="left" valign="bottom">FACS (1:20)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-HLA-DR-FITC (TU36) (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 555560, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_395942">AB_395942</ext-link></td><td align="left" valign="bottom">FACS (1:5)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCW57.1 mDux-CA</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28459454/">28459454</ext-link></td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_99284">Addgene_99284</ext-link></td><td align="left" valign="bottom">All-in-one lentivector with tet-inducible mouse Dux</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA 3.1(-) mouse C/EBP delta</td><td align="left" valign="bottom">Johnson Laboratory</td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12559">Addgene_12559</ext-link></td><td align="left" valign="bottom">Mouse C/EBPδ cDNA</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">TRE_3xFlag-C/EBPδ</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">TRE_ctrl</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiGuide-puro for GeCKO screen</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25075903/">25075903</ext-link></td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_1000000053">Addgene_1000000053</ext-link></td><td align="left" valign="bottom">Lentiviral pooled libraries for genome-wide CRISPR/Cas9 Knock-outs</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiCRISPRv2</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25075903/">25075903</ext-link></td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_52961">Addgene_52961</ext-link></td><td align="left" valign="bottom">Lentivector with CRISPR/Cas9 expression</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiCRISPRv2-PHF8 gRNA</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiCRISPRv2-CSRP1 gRNA</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiCRISPRv2-HAND1 gRNA</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiCRISPRv2-FBXW7 gRNA</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiCRISPRv2-ATF3 gRNA</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiCRISPRv2-STAT3 gRNA</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiCRISPRv2-KLF5 gRNA</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiCRISPRv2-IRF7 gRNA</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiCRISPRv2-C/EBPβ gRNA</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLenti CMV GFP Blast (659-1)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/19657394/">19657394</ext-link></td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_17445">Addgene_17445</ext-link></td><td align="left" valign="bottom">Lentiviral eGFP expression vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSCV-PIG-empty</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/29316427/">29316427</ext-link></td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_105594">Addgene_105594</ext-link></td><td align="left" valign="bottom">Empty control vector with GFP marker and puro resistance</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSCV <italic>S100a8</italic> prom_GFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSCV <italic>S100a8</italic> s1 prom_GFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSCV <italic>S100a8</italic> s2 prom_GFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSCV <italic>S100a8</italic> s3 prom_GFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSCV <italic>S100a8</italic> s2+3 prom_GFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSCV <italic>S100a9</italic> prom_GFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSCV <italic>S100a9</italic> s1 prom_GFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSCV <italic>S100a9</italic> s2 prom_GFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSCV <italic>S100a9</italic> s3 prom_GFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">MSCV <italic>S100a9</italic> s4 prom_GFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">AG Roth (Institute of Immunology, WWU Münster)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">psPAX2</td><td align="left" valign="bottom">Trono Laboratory</td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12260">Addgene_12260</ext-link></td><td align="left" valign="bottom">Lentiviral packaging plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV-VSV-G</td><td align="left" valign="bottom">Weinberg Laboratory</td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_8454">Addgene_8454</ext-link></td><td align="left" valign="bottom">Envelope protein for producing lentiviral particles</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Cloning primers</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a, c, d</xref></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">GeCKO library amplification and NGS primers</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mutagenesis primers</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f, g</xref></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">rm mouse GM-CSF</td><td align="left" valign="bottom">ImmunoTools</td><td align="left" valign="bottom">Cat# 12343137</td><td align="left" valign="bottom">40 ng/ml in vitro</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">LPS from <italic>Salmonella enteritidis</italic></td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# L6011</td><td align="char" char="." valign="bottom">0.5 mg/ml in vivo</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">LPS from <italic>Escherichia coli O55:B5</italic></td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# L2880</td><td align="left" valign="bottom">10 ng/ml in vitro</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">rm mouse IL-4</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">Cat# 214-14</td><td align="left" valign="bottom">20 ng/ml in vitro</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">rm mouse IFN-y</td><td align="left" valign="bottom">ImmunoTools</td><td align="left" valign="bottom">Cat# 12343536</td><td align="left" valign="bottom">50 ng/ml in vitro</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NucleoSpin RNA, Mini kit for RNA purification</td><td align="left" valign="bottom">Macherey Nagel</td><td align="left" valign="bottom">Cat# 740955.50</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QuikChange II XL Site-Directed Mutagenesis Kit</td><td align="left" valign="bottom">Agilent Technologies</td><td align="left" valign="bottom">Cat# 200521</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">PureLink HiPure Plasmid Miniprep Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# K210002</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext High-Fidelity 2× PCR Master Mix</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# M0541S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QIAquick PCR Purification Kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat# 28104</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Bioanalyzer High Sensitivity DNA Analysis Agilent High Sensitivity DNA Kit</td><td align="left" valign="bottom">Agilent</td><td align="left" valign="bottom">Cat# 5067-4626</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">20% PhiX spike in (Illumina PhiX control kit)</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">Cat# FC-110-3001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NextSeq 500/550 High Output Kit v2.5 (75 Cycles)</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">Cat# 20024906</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext Ultra RNA Library Prep Kit for Illumina</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# E7530</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LEGENDplex Mouse Inflammation Panel (13-plex)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 740446</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Doxycycline</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# D9891</td><td align="left" valign="bottom">2 µg/ml</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Puromycin</td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">Cat# ant-pr-1</td><td align="left" valign="bottom">3–20 µg/ml</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">GSK-J4 HCl</td><td align="left" valign="bottom">SellekChem</td><td align="left" valign="bottom">Cat# S7070</td><td align="left" valign="bottom">5 µM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">β-Estradiol</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# E8875</td><td align="left" valign="bottom">1 µM</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Polybrene</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 107689</td><td align="left" valign="bottom">8 µg/ml</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Protease Inhibitor Cocktail</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# P8340</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dynabead Protein G for Immunoprecipitation</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 10004D</td><td align="left" valign="bottom">ChIP (1:10)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">M-PER Mammalian Protein Extraction Reagent</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 78501</td><td align="char" char="." valign="bottom">1×</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dihydrorhodamine 123</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# D1054</td><td align="left" valign="bottom">15 µm</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NEBNext Poly(A) mRNA Magnetic Isolation Module</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# E7490</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DNA Polymerase I, Large (Klenow) Fragment</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# M0210</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FluoSpheres Polystyrene Microspheres, 1.0 µm, blue-green fluorescent (430/465)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# F13080</td><td align="left" valign="bottom">5 × 10<sup>6</sup> per 0.5 × 10<sup>6</sup> cells</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">AliBaba2.1</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/11808873/">11808873</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://gene-regulation.com/pub/programs/alibaba2/">http://gene-regulation.com/pub/programs/alibaba2/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo Software</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo/">https://www.flowjo.com/solutions/flowjo/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MaGeCK 0.5.9.3</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25476604/">25476604</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/p/mageck/wiki/Home/">https://sourceforge.net/p/mageck/wiki/Home/</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75594.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rehman</surname><given-names>Jalees</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02mpq6x41</institution-id><institution>University of Illinois at Chicago</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.12.05.471309" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.12.05.471309"/></front-stub><body><p>The study uses an elegant CRISPR/Cas9 screening approach in a myeloid cell line to identify the underlying regulators of the alarmins S100A8 and S100A9, which amplify inflammation. This approach identified the transcription factor C/EBP-δ as a regulator of S100A8 and S100A9 expression in the myeloid cell line and also showed a correlation between the expression levels of C/EBP-δ and the alarmins in patient samples of peripheral blood mononuclear cells. Furthermore, the authors also validate their findings in primary monocytes using mice with genetic C/EBP-δ deletion. This work will be of significant interest to researchers studying the regulation of immune responses and inflammation, and it also highlights how unbiased CRISPR/Cas9 screening can lead to novel mechanistic insights in myeloid cells.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75594.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Rehman</surname><given-names>Jalees</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02mpq6x41</institution-id><institution>University of Illinois at Chicago</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Rehman</surname><given-names>Jalees</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02mpq6x41</institution-id><institution>University of Illinois at Chicago</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.12.05.471309">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.12.05.471309v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;C/EBPδ-induced epigenetic changes control the dynamic gene transcription of S100A8 and S100A9&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Jalees Rehman as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by a Reviewing Editor and Carla Rothlin as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Mechanistic validation of the effects of C/EBP-δ deletion or knockdown in primary human and/or mouse monocytes as outlined in the comments by the reviewers 1 and 2 below. Demonstrating how C/EBP-δ deletion affects the phenotypes and differentiation of primary human or primary mouse monocytes in vivo and in vitro, will validate the conclusions derived from the myeloid cell line.</p><p>2) Expanded analysis of the CRISPR/Cas9 screen such as addressing potential false positives (see comments of reviewer 3).</p><p>3) Rigorous presentation of the ATAC-seq data including showing all the differential peak analyses and ATAC-seq of the C/EBPδ KO cells (see comments of reviewer 2).</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The manuscript could be strengthened with the following revisions:</p><p>1. The authors highlight the importance of alarmins in disease but there are no experiments showing that deletion of C/EBP-δ affects disease processes in vivo. Experiments showing that C/EBP-δ deletion in vivo changes disease and inflammatory injury severity (not just relative circulating levels of alarmins in the serum shown in Figure 2) would be important to highlight the pathophysiological relevance of the C/EBP-δ link to alarmins. The authors can choose an in vivo LPS model as they also use LPS ex vivo and then assess various parameters of in vivo tissue injury and inflammation in C/EBP-δ knockout versus control mice.</p><p>2. The phenotyping of the myeloid cells in the absence of C/EBP-δ is very limited and needs to be more rigorous as well as more comprehensive.</p><p>a) In Figure 2D, n-fold change in serum levels should be changed to actual alarmin concentrations in the serum but other circulating cytokine levels should also be shown, both at baseline and with stimulation conditions (such as in vivo LPS exposure)</p><p>b) How does the C/EBP-δ deletion affect monocyte differentiation and polarization? Flow cytometry of monocyte and macrophage phenotypes with and without C/EBP-δ as well as with and without stimuli that promote monocyte activation, monocyte to macrophage differentiation and macrophage polarization would be more impactful. Ideally, this can be combined with the in vivo studies proposed in comment #1 which addresses C/EBP-δ deletion affecting disease severity because int he same in vivo study, the authors can isolate various cell types and perform flow cytometry characterization.</p><p>c) The phagocytosis and ROS assays in Supplement Figure 2 are very interesting because they suggest that alarmin reduction increases phagocytosis capacity. In some ways, this may seem counter-intuitive because it suggests that C/EBP-δ activates inflammatory signaling but suppresses phagocytosis, an important function of immune cells. This is a very important finding and should be moved to the main figures but needs to be studied more robustly showing phagocytosis kinetics and some analysis of how C/EBP-δ would increase phagocytosis. Does C/EBP-δ inhibit the expression of phagocytosis genes? Does C/EBP-δ deletion impact phagocytosis of bacteria (this can be easily assessed using fluorescent bacteria)?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The data in the cell line show a direct relationship between C/EBPδ and S100A8/A9, however the data in primary cells is only a correlation. It would be important to show, in either human or mouse primary monocytes, that knockdown of C/EBPδ directly affects S100A8/A9.</p><p>Regarding the composition of the cell culture, flow cytometry can be performed on each day of differentiation to validate the purity of monocytes and determine whether macrophages or other cells are present, which could affect the analyses.</p><p>The ATAC-seq experiments in Figure 6 should be accompanied by a full list of differential peaks between day 0 and day 3 for the reader to browse as a supplementary file. Furthermore, the peaks in day 3 versus day 0 do not seem dramatically different to the eye, which should be quantified. Moreover, the y-axes are not shown for the tracks in 6C. Finally, it would have been interesting to see how C/EBPδ KO monocytes compared to WT in the ATAC-seq data, as well as where day 5 of differentiation would sit in this dataset. From Figure 2A-B, s100a8 and s100a9 expression at day 5 are downregulated in both WT and KO cells. At this time, would the WT and KO cells become more similar to each other, and/or to day 0 cells?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1) The current study did not identify any previously reported gene regulators. Further work is needed to address this discrepancy. It is well known that CRISPR screens could generate many false negatives, largely due to the design of ineffective gRNAs. The authors should carefully evaluate these discrepant results by experimental validation.</p><p>2) I'd like to suggest reanalyzing Figure 1B by focusing on a smaller number (but more significant) of cells. The reduction of screening noise could potentially identify other candidates of interest.</p><p>3) I'd like to suggest validating several other candidates to (1) confirm their impact on S100A9 expression, and (2) further demonstrate the robustness of the CRISPR screening system. Although the focus of the current study is on C/EBPD, the inclusion of other candidates would expand the study scope and warrant future studies.</p><p>4) The legend for Figure 6A is too small to read and should be enlarged.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75594.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Mechanistic validation of the effects of C/EBP-δ deletion or knockdown in primary human and/or mouse monocytes as outlined in the comments by the reviewers 1 and 2 below. Demonstrating how C/EBP-δ deletion affects the phenotypes and differentiation of primary human or primary mouse monocytes in vivo and in vitro, will validate the conclusions derived from the myeloid cell line.</p></disp-quote><p>We now added data obtained from primary cells as requested by the reviewers (Figure 2, D, lines 189 – 190, Figure 2, E – J and Figure 2 —figure supplement 2, lines 190 – 202, Figure 3, F and Figure 3 —figure supplement 2, lines 212 – 224). For details see our point-by-point response to the individual reviewers #1 at points “1 and “2 and #2 at point “2.</p><disp-quote content-type="editor-comment"><p>2) Expanded analysis of the CRISPR/Cas9 screen such as addressing potential false positives (see comments of reviewer 3).</p></disp-quote><p>We addressed this comment in our revised manuscript (see Figure 1 —figure supplement 1, A, lines 153 – 161 in the manuscript and at points “1, “2 and “3 in response to reviewer #3).</p><disp-quote content-type="editor-comment"><p>3) Rigorous presentation of the ATAC-seq data including showing all the differential peak analyses and ATAC-seq of the C/EBPδ KO cells (see comments of reviewer 2).</p></disp-quote><p>The primary goal of our study was not the effect of C/EBPδ on the genome wide genome structure but its role in the expression of <italic>S100a8</italic> and <italic>S100a9</italic>. However, we now performed and added an additional genome-wide ATAC-seq analysis of C/EBPδ KO monocytes and present all data in the Figure 7, A – C, Figure 7 —figure supplement 1 and Figure 7 – source data 1 as supplemental material as requested by reviewer #2 (see lines 278 – 287 in the manuscript and our point “3 in response to reviewer #2).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The manuscript could be strengthened with the following revisions:</p><p>1. The authors highlight the importance of alarmins in disease but there are no experiments showing that deletion of C/EBP-δ affects disease processes in vivo. Experiments showing that C/EBP-δ deletion in vivo changes disease and inflammatory injury severity (not just relative circulating levels of alarmins in the serum shown in Figure 2) would be important to highlight the pathophysiological relevance of the C/EBP-δ link to alarmins. The authors can choose an in vivo LPS model as they also use LPS ex vivo and then assess various parameters of in vivo tissue injury and inflammation in C/EBP-δ knockout versus control mice.</p></disp-quote><p>We agree with this objection. Therefore, we analysed the role of the C/EBPδ-S100A8/A9 axis in a mouse model for acute lung inflammation, which is characterized by high S100A8/A9-level. We could show that LPS-exposed C/EBPδ deficient mice secrete less S100A8/A9 systemically (serum) and locally (bronchoalveolar lavage fluid, BALF) (Figure 2, E and F). Lower S100A8/A9-levels are accompanied by lower disease activity reflected by decreased local cytokine production (Figure 2, H – J), highlighting the influence of C/EBPδ-deficiency on alarmin expression and inflammatory injury in vivo.</p><disp-quote content-type="editor-comment"><p>2. The phenotyping of the myeloid cells in the absence of C/EBP-δ is very limited and needs to be more rigorous as well as more comprehensive.</p></disp-quote><p>To go more in depth on the phenotype of C/EBPδ-deficient myeloid cells, we examined monocyte-to-macrophage differentiation of WT and C/EBPδ KO bone marrow-derived cells and ER-Hobx8 cells using flow cytometric analysis (Figure 3, F). Analysis of the proportion of CD11b<sup>+</sup>Ly-6C<sup>+</sup> cells reveals no differences between WT and C/EBPδ KO cells during differentiation, which is a prerequisite for C/EBPδ KO cells to pass the pre-gating on CD11b<sup>+</sup>Ly-6C<sup>+</sup> within the GeCKO library screen to exclude phenotypes that are S100A9<sup>low/neg</sup> due to differentiation defects. In addition, we compared differentiation to M1 and M2 macrophages between wild type and C/EBPδ KO mice (Figure 3 —figure supplement 2).</p><disp-quote content-type="editor-comment"><p>a) In Figure 2D, n-fold change in serum levels should be changed to actual alarmin concentrations in the serum but other circulating cytokine levels should also be shown, both at baseline and with stimulation conditions (such as in vivo LPS exposure)</p></disp-quote><p>To examine alarmin secretion at baseline (NaCl) and after LPS-exposure we now added new data obtained from a mouse model of acute lung inflammation. We analysed serum and bronchoalveolar lavage fluid (BALF) for S100A8/A9 (Figure 2, E and F) using our in-house ELISA as described. In addition, we analysed inflammatory cytokines, such as IL-1α, IL-6 and TNF-α in BALF (Figure 2, H – J), and various further cytokines (Figure 2 —figure supplement 2) in WT and C/EBPδ KO sera at both conditions, using a bead based immunoassay (LEGENDplexTM mouse inflammation panel, BioLegend).</p><disp-quote content-type="editor-comment"><p>b) How does the C/EBP-δ deletion affect monocyte differentiation and polarization? Flow cytometry of monocyte and macrophage phenotypes with and without C/EBP-δ as well as with and without stimuli that promote monocyte activation, monocyte to macrophage differentiation and macrophage polarization would be more impactful. Ideally, this can be combined with the in vivo studies proposed in comment #1 which addresses C/EBP-δ deletion affecting disease severity because int he same in vivo study, the authors can isolate various cell types and perform flow cytometry characterization.</p></disp-quote><p>We analysed whether C/EBPδ deletion affects polarization of bone-marrow derived monocytes stimulated either with IFN-γ + LPS (M<sub>1</sub>) or IL-4 (M<sub>2</sub>) for 24 hours. We found that expression of M<sub>1</sub>-monocyte associated markers, such as <italic>Tnfa</italic>, <italic>Il6</italic>, <italic>Inos</italic>, <italic>Cd86</italic> and <italic>Il1b</italic>, was only slightly decreased in LPS and IFN-γ treated C/EBPδ KO monocytes (Figure 3 —figure supplement 2, A), whereas expression of <italic>Il10</italic> was diminished, but M<sub>2</sub>-associated <italic>Cd163</italic> expression showed no significant reduction after IL-4-stimulation in C/EBPδ KO cells (Figure 3 —figure supplement 2, B). As mentioned above, the new data set of genome-wide ATAC-seq maybe a useful source for analysis of C/EBPδ effects on chromatin remodelling during macrophage differentiation (Figure 7, A – C, Figure 7 —figure supplement 1 and Figure 7 – source data 1 as supplemental material).</p><disp-quote content-type="editor-comment"><p>c) The phagocytosis and ROS assays in Supplement Figure 2 are very interesting because they suggest that alarmin reduction increases phagocytosis capacity. In some ways, this may seem counter-intuitive because it suggests that C/EBP-δ activates inflammatory signaling but suppresses phagocytosis, an important function of immune cells. This is a very important finding and should be moved to the main figures but needs to be studied more robustly showing phagocytosis kinetics and some analysis of how C/EBP-δ would increase phagocytosis. Does C/EBP-δ inhibit the expression of phagocytosis genes? Does C/EBP-δ deletion impact phagocytosis of bacteria (this can be easily assessed using fluorescent bacteria)?</p></disp-quote><p>We thank the reviewer for pointing to the importance of the effect of C/EBPδ-deficiency on phagocytosis-rates. We added data on phagocytosis of bacteria and found higher phagocytosis capacities of fluorescent <italic>Staphylococcus aureus</italic> (Figure 3, C and D) as well. Analysis of Pattern Recognition Receptors-gene expression revealed that <italic>Ptx3</italic>, <italic>Dc-sign</italic> or <italic>Cd14</italic> are up-regulated in C/EBPδ KO cells, which may explain higher phagocytosis rates due to increased pathogen-recognition (Figure 3 —figure supplement 1). C/EBPδ could act as a suppressor/regulator of phagocytosis, but these mechanisms need further investigation which is behind the scope of our study on regulatory mechanisms of <italic>S100</italic> expression. For our question, the most important observation was that C/EBPδ-deficiency does not dampen inflammatory responses in general but that its impact on S100A8 and S100A9 expression is rather specific. However, we agree with the comment of the reviewer that the phagocytosis and ROS assays reveal very interesting facts, which is why we moved these findings to the main manuscript as suggested.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The data in the cell line show a direct relationship between C/EBPδ and S100A8/A9, however the data in primary cells is only a correlation. It would be important to show, in either human or mouse primary monocytes, that knockdown of C/EBPδ directly affects S100A8/A9.</p></disp-quote><p>Please see our response to point “2.</p><disp-quote content-type="editor-comment"><p>Regarding the composition of the cell culture, flow cytometry can be performed on each day of differentiation to validate the purity of monocytes and determine whether macrophages or other cells are present, which could affect the analyses.</p></disp-quote><p>We agree that validation of monocyte purity is very important at this point, because altered differentiation kinetics would influence S100A8 and S100A9 expression. Flow cytometric analysis of WT and C/EBPδ KO cells reveals neither differences in the purity of CD11b<sup>+</sup>Ly-6C<sup>+</sup> cells nor of differentiation kinetics (Figure 3, F), which is a prerequisite to compare time-point dependent S100A8 and S100A9 level of WT and C/EBPδ KO cells as we did.</p><disp-quote content-type="editor-comment"><p>The ATAC-seq experiments in Figure 6 should be accompanied by a full list of differential peaks between day 0 and day 3 for the reader to browse as a supplementary file. Furthermore, the peaks in day 3 versus day 0 do not seem dramatically different to the eye, which should be quantified. Moreover, the y-axes are not shown for the tracks in 6C. Finally, it would have been interesting to see how C/EBPδ KO monocytes compared to WT in the ATAC-seq data, as well as where day 5 of differentiation would sit in this dataset. From Figure 2A-B, s100a8 and s100a9 expression at day 5 are downregulated in both WT and KO cells. At this time, would the WT and KO cells become more similar to each other, and/or to day 0 cells?</p></disp-quote><p>We are thankful and agree for this comment. Indeed, we completed our ATAC-seq data by adding C/EBPδ KO cells on day 0 and day 3 (n = 3) to the analysis and a comprehensive list of all regions with differential peaks between all four conditions (WT and C/EBPδ KO cells on day 0 and day 3) (Figure 7, A – C, Figure 7 —figure supplement 1, Figure 7 – source data 1). In our revised manuscript, we also now statistically analysed differential chromatin accessibility between all conditions by specifying the adjusted p-values (padj) &lt; 0.05 and log2 fold changes (Figure 7, C). We agree with the comment of the reviewer raised above that adding data of C/EBPδ KO cells fills a gap between ATAC-seq and ChIP data.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1) The current study did not identify any previously reported gene regulators. Further work is needed to address this discrepancy. It is well known that CRISPR screens could generate many false negatives, largely due to the design of ineffective gRNAs. The authors should carefully evaluate these discrepant results by experimental validation.</p></disp-quote><p>This point is a very important and justifiable note. The impact of previously reported gene regulators, such as ATF3, STAT3, KLF5, IRF7 or C/EBPβ on <italic>S100a8</italic> and <italic>S100a9</italic> expression was examined in our study by creating specific KO cell lines of these candidates. None of these suggested genes caused a relevant reduction of <italic>S100a8</italic> and <italic>S100a9</italic> expression upon deletion (former: Figure 2 —figure supplement 3, now: Figure 1 —figure supplement 1, B), thus confirming their absence in the CRISPR screen. In addition, our screening approach intentionally excluded factors which induce a general block of monocyte differentiation to exclude indirect effects not related to direct transcriptional regulation of these two S100 genes. However, transcription factors which show both, effects on general differentiation and <italic>S100</italic> expression, will not be detected in our screen. We discuss this point in our manuscript (lines 141 – 142, 349 – 352)<italic>.</italic> Taken together, in our opinion CRISPR screens have major limitations which do not allow reliable identification of a network of factors regulating gene expression but can be very useful for unbiased screening for individual factors. The latter has to be confirmed by independent validation experiments as done here for C/EBPδ.</p><disp-quote content-type="editor-comment"><p>2) I'd like to suggest reanalyzing Figure 1B by focusing on a smaller number (but more significant) of cells. The reduction of screening noise could potentially identify other candidates of interest.</p></disp-quote><p>We agree that one might retrospectively argue that a different gating strategy may have improved our screening approach, but reanalysis of the existing data is not feasible since cells were already sorted, processed and analysed in the CRISPR screen. However, analysis of our actual sorted cell populations (hits negative and reference positive) by immunoblotting for S100A9 (Figure 1, B) clearly validates our gating strategy and excludes gating as a major bias of our results.</p><disp-quote content-type="editor-comment"><p>3) I'd like to suggest validating several other candidates to (1) confirm their impact on S100A9 expression, and (2) further demonstrate the robustness of the CRISPR screening system. Although the focus of the current study is on C/EBPD, the inclusion of other candidates would expand the study scope and warrant future studies.</p></disp-quote><p>We agree with this point and present now additional data showing that single knock-out cell lines for further hits as PHF8, CSRP1 or HAND1 do not dampen <italic>S100a8</italic> and <italic>S100a9</italic> expression extensively, especially in comparison to C/EBPδ KO cells (Figure 1 —figure supplement 1, A, lines 159 – 161).</p><disp-quote content-type="editor-comment"><p>4) The legend for Figure 6A is too small to read and should be enlarged.</p></disp-quote><p>Thank you for this annotation.</p></body></sub-article></article>